var title_f38_42_39584="Miller laryngoscope";
var content_f38_42_39584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miller and Phillips laryngoscope blades",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39584=[""].join("\n");
var outline_f38_42_39584=null;
var title_f38_42_39585="Steeple sign";
var content_f38_42_39585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52418%7EPEDS%2F64512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52418%7EPEDS%2F64512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Croup: Anteroposterior radiograph with \"steeple sign\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEASwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Q8Lail/pox9+L5WHt2P+fStmvIvhNrxbXH0+Vv8AXRHb7lef5Zr12gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArF8UX8FpY7Z3I3c7V6nH+f0rary/4hamsmsrbxtu2EI2P4QOuf1oAvatqnlaMtxDEqbQMFjk7f/1183ePPEv2zULh5GUOWxs7H3r0Pxl4sC2VyGIitUXaOeT7fWvmfWNWM907qx2kk5JyaAOh/tQ3EGwt5UXcDqa5y61DbMRFsRewNU31D91si4J6msxwSxLE5oA+l/BOuPp/iqzvWYt5UgJHqOhH5Zr6ut5o7iCOaFg8UihlYdwa+JNNuTHfqQf1r6J+E/ixBGml30uEbmF2PCn+79KAPVqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjuJVggklb7qKWP4V4V4qvNwlO8ZJMjyep616b8RNWSw0j7OHAknOD7KOpr5o+IHiT7L5kSEmIDrnlv/rUAcH8SdckkRk3EKTtVf615ouWO5uSat61qEmpXzSOTtHCj0qso4oEOHHTrTW6808jAHvTG60gPTY7rbeA7sc16J4YvclQH9xXkRuf9K4Ndh4bvzFJHycA0xn1N4D8UNIiWWpSEnjy5WPT/AGSa76vANCuQ8McgIOQM16h4c8QFI0t7xi6cBZO6+x9qAOvooBBAIIIPIIooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKpaxqdro+nTXt/II4IxknuT2A9SasXVxFa20k9w4jijUszHoBXzn8WPGr65d+VbsyWMJPlp03H+8aAM3x942/tW+nuC33jhFznavYV4l461F5lV3b5mXp+NbWpTEuSTXC+Lbjzb1IweEUZoAw0FSjpTFGBT6QiSToKibrTic49qaetAG752bgEHINdTo033cV51Z3LKyqxyB0NdhotxyOaYz2/wXqIe38pzyvTJr0vSZ1dFw2D714P4avPLuUIPWvVvD9/8wXNAHrOg6r5arFMxMZ6E/wAP/wBaumBBGRyK8zsrkSJ8uMV0uhaqU2xTnMZ6f7P/ANagDp6KAQQCCCDyCKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApk80cELyzOEjQZZj0AonljgiaWZwkajJY9q8t8b+JXvy0MRKWacgf3/c0AYnxL8YyaiWt4GKWSn5VHBc+prxTWrhnd3J4rX8SaiZrhgDkKcVxOrXu5Tk9KAM+/uBv64Arg72Y3V7LN2diR9K2tZvSsTgH5n+UewrBUYFAhwFOpB0paQBTT1p1NPWgCug5Nb2i3ZBAJ5FYkX3m+tTQSGGZWHTvQB6ho95t2Fe3Nem+Hr7cY2J6ivE9Guc7celeheGr04255HIpjPaNKvACOeDXSWkgJyhrzHSr7JQ549PSuy0y93cZ49KBnomkansUJKSU/9BrfUhlBU5B5BrzuCboc1vafqMkKjDbk7g9KBHT0VVtr2KZc52n0NWgQRkEEeooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtf30FjFvnfHoo6t9BVTVtXisQUQh5vTsv1rh9TvZJ5GlnYsx70AJ4m124vQyk7Is/LGOn4+przLxZqPk27Dfy2a6DWb8bWJYADmvKPEmom5mdt2UXgCgDC1O8yGweetchqd4OeeKu6veABvmrkL+5MrFVP1oAguJTPMWPQcCmikUcU+kIKKeFGOetNZcfSgBKaetOpp60ARR/ff61IRkGo14lce5qbtTGaWi3W1gjHlen0rvdGuzHKj5+U8GvL43MMqyL2612ei3QeMYPGMigD13TbnBTaRgjpmuv0i+IfGefTNebaJdb7dDnleDXU6fP8wbPFAHpdle71G7jA6VsWlwccEYrh9LvAQqk849a6G0uV2En86BnTRXJUEoefSr1rqRB5bBrmYrgAYJ496spKDg55pgdjb6moXEmW75rQt5fOiD4257ZrkLBHnmRA4wxxk+ldYgjt4UiZwO3JpCLGaKiaMPyGPTAweKx7ye4tywDEjPagDdornRq5iK5kOD1zTW8SRKwDTR5/ujmgDpKKx7bXbWVTulUHtxWlBcxTD926sfY0ATUUUUAFFV7q4SJDk84rIfUjgnzDge9AG/UT3EKZ3yoMerVzNxqIYnDE5rOmuzg5PBoA6yfV7SJSfMLY7KK5/U/EckgMdt+7U9xy1YlxdBz97OaoT3SJuII/OgCW6u9vzM2Seea57VNUDZRWwai1PUlGQGy3YVxuu6p9libDZkegZU8UaxkGCJjj+KvOtavwqkZ4q3q1+RuZm+brnNcJrGobicH6UCKuqXpdiAeazFB6nqaXlm3N1NOAxSEA6Uq9RRT1XHNADqD0NFFMZFTT1pzdTTT1pCI+k7/wC8alHSo3/4+ZP941IOlADWFanh668ucxMeOorNPSmoxjlV16g5oA9b8PXWGK9jXWWF1scDPBrzDw1fiQg5+YcGu4sLoHAPXpmmM7a2vBGylDnNdNY3nyAAjPvXBW86uwUZFb+n3OEwTz9aAOxW5JUHJJHar8VyTGDmuXt7oYwTWhb3AKEZ7ce9MZ1Wl6g0dxHnBUHit641mQEF9roexArhLOUPcIvOScDFdBcK5iZAASOR60Abqa5DIuIkEcyjpnisu7vJ5Hx+dcpLdTwzbjFJkH7wXirEuvOoDNGCuMHjBoA1Z9k5CzICD9R+tNg0uxAJdpgT0CnpWdHrVvOcbyhHYrV9dRSGM4khOfU5oAu/YLVVVIppVdjnLGtzQbf7K5YvufpnNcXDr6rOPP8AJ25zweR+FdBp+v2flnezA5J6daAO4Rty54J9qqXdzKsZ2RHJOPcVyUutSO58qQxxjsDVC51ybk+Y5P1oA2dYkljgLTSbSf4RWCLs4G5vw9KoanrEk0e1jhs1mLec8tQBuS321zzxjtVKa/ZmK7sVmSXGQTuqu8+BmgC9Jd4JJbPas3UNRCIR296oXN5tJ+asDUrwsx2sdvTr1pCC5vvmeVmz9a4jWtRM0zHPyjOKua9qHlxeWhwf5Vw+q32yM880AUtf1HAKgmuVdzI5Zunan3c7XMxYk4qNRQIcBS0UUgCgEjpRRQA7f7UoYE4plA6igBX+9TG609+tMbrQA2Xi7l/3qeOlMuOL2Uf7VPHSgBaY44NPpjHigC9pFy8EysnXPI9a9A0i/FwoKHDdxXm9gCX/ABrobFnjdSjEEUAenadcsMY+lb1jcnuefSuF0nUQwCTfK3r2NdJZy45BBH1pjOuguTx3HtV2G6OQMiuYguOMk81dhnOR/OgDvtIdTdx5YADB9zXcWt1bSEFdqt6ZryHS5nkuAoY4xk810cVwycoCGoGeiXSROD5oURbcgKM5Ncvf6RHck+Wyqc8HNULPW3QhJn47Z7VpreQyxPIjK2B2NMDnY/D94WfymRsHHBBqRNDvy2J42P0GataZehZZQ54J3CtGbXIYguJJHbGPl4oA5ZdAvo7pv3L4B7rWtb6TdZ/fjb7ZrTtdYjeSR03ZweCamW5zkF+RQBJB4ehe0Lm5ZJB2J4rI1Kzkt+PMD+hFaZ1yCBSJW8zjGB2rKuddt5WwUCgnGeuKAMTU98LKHzk/jVPz+5q3rd0k2HYjI461gGbK47UAaJuA3IIqpPd4yueKptL1O7iqFzOFBJP4UhBeXhDNk1hXd599ugXpTL26+Zjmud1W9CxEZ5NAGfq15vkY5zXE6zeGaUxqeO+K0tXvtkTY+83C1zi5JyeTQIcoxxTqRadSAKKKVBzmgBKKVutJQAUUUUAFNbrTqaetACXnGoTf7xpR0o1AY1Gf/eNNJAFMBxPFIqmQ4HSljjaU9OK1LS0PAC5NIBLC3OVwORXQWUB3crRYWZDDI6c4xW9bWpyBjimMr21uTitiykmtwBu3L6Gpbe3wOFqysGSOKALUV8rKoddtaVvIHZdp69eayvs+eoFTQQsnKkjHpQB2nh7JuchRgda7qw0+OVgwYFSORnpXl+jT3KKwLfLnqOCa6Ww1Oe1cOjsuD+dAHXaxodi0BaJz5inHPQ1xuo2dzZBzBI+MYBU1rnXftK4mJB9KhvLpBbMdwy3TIoAwNPvr37Qf4zj+Ja0ReX2OYYz/AMBxTYLi3a5AeKM57j5f5VqpPYRgHJU7f73WgDEm1G8XjyxGcdQvSmRajqDnZHLI+e2K3mmtp1RQNzDnJOc0+GdIhuWNBjoBQMy47bU2Tc8DBf7xFQOskZIOC3vXZwasn2RknljRT03Cuc1Waydi8RLuOozgUAc1qjlJVyQDjmqjTkDPA7U7W5Q0+/GOMVkvcYHGPxoEXZ7javXrWJfXhLEHFPnuu5Nc/qF2Ax5xQA69uBz0rj9avguefwq/qWo/u22nJNcZqUzSScnrQBBcStcSlmPHamgUijinjpSELRRRQAAZNPYYQ4pIz1FDNngUANooooAKKKKAE70h60pPNIRzQBr+J9LFpfS7NxOTyayobctgtXe+ObXbqEhx3Nc3bWpbGBTGQ2tviuh0y1IGStFlYAYL9q27WLbjigCW0tj1284rXtrbA+7SWUPQt3rZtoN3PYdqAK8FuRjjFWEgw5yBirscWAMjinLGA3HWgCsIBjOODT44R0x8pq4IsgZpyQOx+VT9aANXQ7F7hCqKOvGeM11Fn4cmuI9rqASc59Kw9JWSGJSHwR0ArqNNvpZFZJHKnb8pBoGc5q+hXVnMyA5GOCDXM3t5JHP5dzG5VeNyf4V6TfO5jZ5W5UYBNcXf2yXEjNvCnPcdaBGPbGGS5TZMQM98itU2mEJEy7en3ql0rRnku02GN8n1xXUSadKgA8hCg9QORQBxZc2zE/aBu4A2/NTH1a53EQhn543DGBXR3+kvHcN+6Hl54NT2mj27uqmPk980AchJc3dwfnXn61Wupp15Kc+oNen3Phy1iiAt2EhK5964zVNNlSUswCjtQBxV9cT+aVYdKz5Jpufl/WtzUohJIWXtxkVQaHjjpQBh3bTtx0rFu4nY4Yk1091FnGKyruMlqAOTvomRSK5rUFxJkV3moW4ZT79K5HVbcgnigRlDoKkqJeDg08GkA6iiigAooooAKKKKACiiigApDS009aAPYfG9mDdu2OK5y1tQoHGK9B8X2+6Vjiuat7UfU0xlWG34GAK07S3x15zUsVrj/wCvV63j59hQBPbx4+nHStO2Udh0qO3iyoHOK0IYdvWgB0UYwOMk0+OFjLtUcGpkTIpFVt3AIIoAmNpgD1qQQHcARgjp7VPDLtUCZCTnjFWGjWVRs+ZvTvQBJZwscDbketb1pptwY9yqWHbjtWZo8s1s52qGBPcdK7jTr8rEhjjXd3z/AA+2KBnG65cyLEICpV+ucYrl52m3nzI8+nFdt4vnS6uC2xVbp8tcfvkifpkE9D0oAs6PLIHZgdpA4rVa8uRg+cxx2PSreiuzREmKLnnJ9K0ZUglUBbeMvjoOKYGRHflx+9BBNTWl1GzKScAHBHpVee0EzERgpz0J6Vp2Hh+W4iwjYPUsTQBWvbyYYW3YIMY3d65nUGlOcyFs88muo1HQJ7VSXzx6GuV1ENExBHI9aQHOzxkzNkd6ikg+UnjPrWnIofOevrVVlyKBGJNBlz04rNvLbnoK6KWPk/zrOvIjzxQByl3H85GMj0rm9Vtw24gciu2uYcknHOKwtRthk5A5oA8+u4SrkgVCDmui1OzxkgcVgTRFDlaBADxS1GDmng0gFooooAQ0UtJQAtFAGQcUUAFIaWigD6W8R6bdXLbooXcewzWJb6RdqCPs0uf9016naRGSMeW6A46NWraWlwEYvGNvYqAaYzx9dNuAQGhcc91q1DZlR9w59cV68lvuGHRendaZ9ijY8wI30GKAPMYYCrYrTtbGWdgFU49T2r0y08N2kmGmthu6he1X/wDhHrMJ9zYuPwoA88t9FLqNzH8KtnSY41CqRnrnua39Ums9OVlhnWR/7prjtR164RzmBwo7qOKYy69mgwpIPNSRWRgjLYDO3TnnFc0NVWZ/nZ4yT3HFb2n6gPlErbo8YBFIRbjVuvOR1FbGm3Gfl5xn5s1BDHDcqfLkCv1G7itXSrNhJiVR7nNMZg6qoMxcHHPpnis5BmVcDdk46V2mraVF9n35BU8EjmuUfSXEn7mXHPANAG5p8cAg2lYwzDkbqtm2SMhvK3HPZ81irpM5RRtRj1xu6077JfRfMqkYA6NQBpXkcQu3eJgR3FTBn8ncHZUHPBxVGCO5mVUMZHueKtXwmtLcKyZGOCKAKWo38vlhEYyOOMtXGazJLNIA/XPpWvcyzSOwRSM9z2rLuYmDfO+89wOlICgtuGXHJz14okt1WPDABatTWMgdW+YI1MlsmwB8woEYrJzjtVKdc7h0rXlgaJmVgQT1zVCZD2oAwLiIEsMY96xr+3BB457V1V3D3xwRzWbcW+4H1oA4q7t/lIIrnNQsSrEgZrv7uz56celZF1ZZzlaAPPpoCrfKKiDdjwa6a/08gkgViz2pyeMUCKoNLkUjxOn0pu71GKQD6Q03Ip7qUOG60wGinCm0oNAx1FFNLAUhH1rfxsVVlJHA5BxVzStV1C2GFmLoD0fmklUNAufSpbCDc21VJJ9Koo2YNe8wATwZJ7qa6jQXgYCZ423n7q46Vi6B4alvLpTMp2LyQO9ej2WmxQoPk24FAENuIyhkdAq+4rC165huFaK2uQg6My1s+I9Xs7Cwljd4wxQgDqfyrxDX/EpEjiJWcqeCTigDobjTrMyn96ZCOuDVO4skUYiBA7561y9j4sukmUFI9o455rej8SySbv3cZHfAoAJNJWaI5xn1xWatlcWdwcfcXkgdCPpWzHrEUu3zF8vPXHIqeXabZmTad3cc8UgHRui27OmcN8uD1Bre0Cd3TYzcr92siOEeTHIMFTwy1uaXahmEltn/AHO/4UwDUfNaEoHOzPc96xhDcCT922TnoDXRXkbKh3oSRWLHPifIxgEUgNCJ7iNFDDPsRRI8+wsgxn2NSR30a5QttOOvbNWBdLsVA4bOeh45oAk02QRyLJP84HYUmr3K3BAwUzwMVJbRmVvlGGBHSodUhLKY1bAA5x3oA5y7t4VUmW43N6CqkcMZbMSkntla057OIRrl8MOMeprF1GzvDnZcIE9FOKYE8kZdSuAefWnR2j7Mbc/hXNSadqHm/upAD67q1tNTVrYr5pDx989qQixfWCyriQAkfnXN6npzQfMvzJ2PpXpFtp8l/AMFQ3sap3fh27+ZXjBVuvPFAzyy6iOwd/as14DzyMV3Op+Fb6GX5ItynkEGsW60i8hbMttIPotAjkru3APPBIrMnt88Yz2rq7q1OCGXB9xWPPAVOGHFAHN3dhkcrWHd6aMnAwa7ox7lwx5qjcWg+tAHnlxZ7cjFUJbP1Fd/dWSkH5ayLnTyCcdKAONktSDwMUtw8jnlF4Fb89pjrVOW19qBGHn1GKUEdq0pLXnpVd7X2oGVc01+tWGt2A4zUDowagR9p6dYvfxokY6jlvau/wBA8JiCPe2GJ5JPBrlfCpHkK7v5cQHJzXS3viryojbWfHYsev4UyjqLc2mlKySSqJG/hHWsHXfExRXjXCJ+p+tcVPqbC4ErSFm3ZPOc1l6tqZuJHbBOf1pAQ+IdRbc3mZZW6c9a4S+fzJSM5J5rotTSe5iQojYHGSKyTpU0kvJVVHPWgRkk7YCgwJG5NXdLkIkKFutWH0sef80yg8Z46Vp22kwBVPmuxAzkYAoAZIUUAbuTxU2m3jR3PleYRE3B9jUqaVFLgI8iHOOeRUI0i5jnUIpfJ4KigDqrO9McaI6hhn8a7jRYUlijubdxsxyp6g1wljatGw88Eng+wr0Hw4m2wbpgnjNMZoX5iOnB8gtuAIB5rnBp0Es5cBgfc8VsXkDYBVsA88GobOGQF8SAjHcUgKS6LCxLCUrj2pqaWqucSH+tbTRTIgKqCep4qm6yI53LtFMC/p+lxGLfG7ZU9cVQvbbbIS7jBPOK0La7kittgC7SeSRVPVLmCGBmlQs38IHGKAMq8ihRNwUAnueTisCdIzK+F3Zzya0tU1S3jg811wu3gbuTXC6r4uEZK28Sg89smkBpFsvhE68GtfT9wUAoMe/avLbrXb+R9yzFPYVNZ63ftIAJ5DntQI9s0zZvBYbTnsa6WXT5JIlaKU+1ePaLfamzKGKn3JOa9O0PXop4lhu2aGU9CTxQMj1S0uFhYMCSvOR61i5n/jQsPcV196kzws0U/bNcHffb4yxhnYOpztPemBJdW0UwxLadR12j+orOuvDWlyIDPbxKx6kDH8qqtr+oR/KZQccEFaD4lnPE8St9KAM6fwbpjk+UGGPRz/Ws+fwTbchWk/76Fas/iKJTlon/AAFQf8JNaSZEqSLnqaQjmrvwVg/LOw+oBrGvPBV0CfLkiY+/Fdtca5poPJmbn+EVSOu6USN6XQHc5oA8+u/BWoYJ8qLHs4rKufCdzD/rmiT2DZP6V6m0mm3akW1+yu3RZeKy73T5IuHUFf72SQaAPKb/AEGS3TfnK56isaW1YHkfjXqniJIvscUa9Se3auTmtEPTr9KAOOlgOKqSQndx/KutuLNehFZc9l+844FAH1TYSFNPTAJOOB71HFHcTSOW4Gan0pSbFWAzgVKksUIkaZgSO1MZELRcgn5z9abPbhAeQCOuBVO/1hGjbyAAw64FYlxq8sisp3KDSA19Qnt4rc+Y42jqCayJNX09cAJubOOBWVfSK0XJPJ5HrWQyFJWz0z+lAjfuNVi8xQltuHqTitTTtWRsZtgFx61ydkPNTAb5s5wa3LOJ4woKnNAHQ295avL8ylPp2rptCgjlgkkjIkBzyOorh9rkbmQBc44FdJ4bvfsbx7c7c4YH0oA6e3to3RhKnHqO1dJYW6xWqiFsr7daxIriAHDZAJ4OM1vadFsdCrgxkZBz1+tMYy8RxAxwT34HpVCOQpGTg5JArptQVViQnmqIsoZBgNtOc8UAVIr5MYKPSStlTInA9+PpU39kc581CpOc9zVyKwjWM72zkdBQBnlQIFbOeMmuK8Wak0cxTGR7V6VqEEUVpnG0AevSvONdtYrqf51Zh7UAefazey3aKqghRxxXM3KMT0OQa7+6t4xlY41UZ44rMu4E8wlUXcc44pCOJKERLuHf9K09GVBMGPB6CtaWIGJQ0eR6EZFFtbQNKFKbD6qMUAb+nzK6AqQCBn61qQzEZGc+lYdtZMHzbuCMdDVt99uC7g7MdqYzp7PXptPVQSXjIwVbvW4LddVsRdWa/MPvIeorzm3uBdyb5CSi9BXYeFtWa1uUO87f4l9RQBleINLKKbhEwRw4x0965x4+envnFe43mmQ30YeMK0Uq8j615lrOh3On3rxPG2zPykDqKQjkZ4Bjofpisye1Lgjbg+tdgdNlc/dx9arTaYRklgO3FAHEyWjg4ZD9ahezO04X8a7ddKRslmJx6CnpoiFuFYj1IoA8+exJPygk+wqaO11BFHlmTb6HOK9CTTAr52qB61KLWMDnBPtQB5hd6Rfzld8fHYjoKqyeHpeu4FvSvUpo1cFVUgDtWXd2g2g5AFAHl95o0sYyyVhXFrtlIx+lerXMUeCH6ntiuP1jTgL1vL+6QDQB7NpErJp4xjlcGsu7sJHeRozuXrjNaWkIZLBAvcd6vWdgNzl5DkdQopjOHlgnjPzIeeMGqjROrEkcDmvRZdOilb92hZh03Gq0tg0QU+XGvrgdKQjzu5gMjIjI3JzwKj1K2XIEUbsOh4r0O705XxKGUbV5AGeayp7Xed6uCF9B1oA4mGznWWMlGOPSuotYZ5ChWJx9BV2Owmkn3D/gNdVpem3KhXYHjsO9AHLvauMeZlSeelXbWFgq7eorqre1eWUiVMjuGHSr6abC8oCIoA9s0xmTYByoD9SM5rpdILPbgAZG8kZ9MVXm01RCzxfeUcj2rV0O3YxqcbQDx9KALFwj5Qb2HFTQwv5XDD05qW8VlhzwD0z60yyJMahfmOe9AC+VLnHAHXigF0KkqMd6t9Ms3ygDHNRF0kIwRzxQBFeypPasJfl4zmuNumt/MbAbYwI5611urRjyWQd1/KuLu0y+OcUAcPr2rW9lJJDglwec9K5u61xjIhGB7AVo+OtPfz2uY19mH9a424LfKwAAApCNp9UuTIo3Aj0og1x/O2yxIwBx9KzDvlRAo59aqy5gcj+ImgDs9O122MhR1aMngk1uRyLdRqUl+X6151HhI9/BJ9TUkN3Kku5JGHptNAHp40+ExjKhSRnen9afaQS2sytjcvqKwtF1qQKiXQDgDG/HT612Fg8dwgkiYFiO3emM7fwpcGeweByTjlfYVe1CNHsm+1qHVDyT1wfSs7wzD+43j5JM5HHWtTUQWt5UYckEfh60AclcaMj/AD2rbkPbuPrWJf6cUb50APXp1rZSZ0X5WKnrkGrQvy67Z0WQDgZXmgDk4rZvuqnfGatLp9xKPk+77CuysNOsLpHkVHjYYyAcirLaaIF3Q4MfqBnikBwb2TocyJgAcFuapfZJWboSv51389gJoZJJlxGB361xGvTSLuSzyI/VRTAzbtYYFJllUH0zmsK7u7fGBvYfTipZYC2SxyfeqrwA9BxSAy7mZG6I4rn9QLfaTtBxj0rsxpc0o3BAq+prH1LR5FucZXoKBHc6FF5ligJwcdc1sWGo2tn5iTsGwByBk1gaWSdLTBIyKERXkfOcCmM3bzXIBETaxkg9M1z0+u3khaNY1A55xmoZZFVeTjGSABVa4vFEa9CcelICNLm8czN54A7A1lzSTrIQZiD7HilS6O5up54we1O8h5Zw235Qc5NAi9o0N086b5JMfe613FrJLHFjzGGDkZNZHh6MMu5lOex65rVkmiDbRnOOvvQBcs9SuFcZZWXtkV0WjXEUz/ONpyACOc1yEIReWOc9DVhborIqxscdTimM7CVtjOIj9K0NF3bTvycnjtiuas5ZWZTI2R2GOa7WzH+jxkjnFABchGjKP3FUI7ZkJ8o7h14NW7qFnO4McelVokkjkBEgwDzxQBXdbiWQKFfAyMHt+NXLazdTmQgDqAOoq58/HKj8KeKAM/UIs/dXk55zXPSaX5jGQOmO4zXV3ShoSCwUeprOjhTy/YH1xQBwniDQ4pkYNnBGM9q8l1bRFsruSIu20cgZFe9az5KhsuuMdua8t8dGBZVlAZgGwxxSEcwlhbpDv8xxgdRiqMukTSHdFIsinnnrWuZrV/kG4ZAPNTWot8gpOvHOKAOZuLaSMYkhZR3Oc0Q7QfkB9Oe1dLNbSM74CvG3TBqKOwMrKiQEEHsKAC1YbV9cda6DQHuIpgwJWPOcdjRa+Hiib8hj2U1oQQPA+GQqenI4oA9M8O38dxEpT5ZAMFSa3rtBNauAcErwfevLNOnaA+ZG2COa73QNWj1W3MJIE6dQP50xnNzQtFIySDDD0NRx7lPqBxiuo1rTzc2/moP30X3gO4rm0TPPHXFAG/oT/I6qCdwwRWpYyMCY2ywJ79qx9HwkmM/KeuK3YkRAG69h70AUvETGOw2xgDdxwccVxhg+Uhhx2HtXb6kFuItu7kYOMVz93bBQMfnmgDgdRtfLunXkDPGan07ThtEsyhj1CntWprcI8yM4HTHNTxx/KOPlxj9KAKFxBlAR1x0xXM6paM92SpAGB3FdzshQFriRVOOFJGTXH61dWqXzLFvK4HIxigB2jqW0sAZOB2qewgmaXHAB9am8MIWsVUda6azsUYuE2hgtIDnLnw/JOSzygc/wjNQtoMQJjDvI446YwDXTSolvzJcx5/M1BBq9kzkNuZl6EjtTA52z8M28NwRc/dx2PWrMumacu7aHOB0Bp+ra6pdkhhB9M1RtdVlLhDbxjceetIDotPsLeKCL7MHPGcZqWbTYXbcUZGNSabqmwDdaqT2wa0ze203E0bx/7pz/ADoAw30WUjdGwIPqKktdHuDIuFXj0NdButCirFP36MMVes4T8u0g5HYUwM7TbN2nCyAZBxgjrXYKMKB6CoYrdFVSVG4DrU9IQVXdSrEY4J4qxSN25xQAoopOg5paAKuoNtiGRkVz9wzFGyePSujvUL27KBkmseSwd4snj8KYzmb2ElGPQnoc1y2vaal1aSIwBJHPsa7m7sJeVB4PrWRdadOEKlEZsetIDyJINkqo68odvNWbu2SGEvs4YY/Gt7U9EuYr5nMY2N7069sXktUTyXDjkE9KBHL2LSKpETMCpzweK6HStWKNsu0zg8lajsbSOyjkMjAk461WIUzDngnpQB3VjPbXce2Jl3n14NXTHsBV1BT3rgGuDBxESH9TWjpmtXEeRcEyxjsx6fSmM3L63DL/AKJkD+7S6FPNYX0ci5WRTyG71bspINQAa3bbJjJU9avrbK5CTLtYdD6UgO7tZluoY50+64wQe1c7qNmLe9cKoCscr9DW5odu1vp0aMck8/h2pmsxbljcDnO00CKWnQAvz91QRW0y4VQeWHArLsoyCB07mtcruXDc0xmeyFnyeo6nqKpXsSkZ24HathofkIXqKqXUHyZxg4oA4jW0y6cdBzVCOC4myYHfj3xWzrcOJVHbH61paHapHEu7bk5NAHOxeHpZ8tMWYnuDWXqehRpdFTHzgV6eQiIAoABHauQ1wP8A2g+DwQCOlAHMeF2cWOVOPf0qeW6lVnVGOWHY81W8Ncac+TikgcidnblR6CgBWt2O3zCxZu1Rz3FtuaLIDDqxOKguLu4lnPlxOFPy5wcn8arjTbtpy3kEZHfvQBLcyQ4Lr97GMDmp9AtnmmMzqSq8DipdN0W6uJNnktjv7V32m+H3ghjjEeB3JoAyreAgcoRx61KsG98FiAe9dBHpMis25Uz9apXenzRhmKgKOmKAMmaECUY5HqTXQaHK0bKrDK44NZMdrLJIqlHJJrpNPtWhjUFG3ZzkigDTRg65FOpEGFwBilpCCkYBgQaWigBiRlerM31p9FFABQeRRVa5lkUERqM+poAivLcNEccADOaxrqxdwWUqCewNamGdGR1IyOueKyNStJFHyAnA60xnP61abI2eR0V+v3hWAhuCoKKCc4HzVqeI7Rtnmc/d+7muBkvLyORkhYptPOD0FIDo72zDKDcLkE+lZ01hbFx5DFM889KrNrl3iJWYSIOu4Vfg1iCQiOeIoD0PagCBtOmj5ZVmQnORyalSxOehRR/e/wAK6i1jtzGs0QG5gBx0qW5tRcbUmjO/1WmBzdu7WsoaEnIPX0r0HwrPHq67bpQJF6EfxVixeHWiBklBkTrt9K19L+R1EKmMr+lIDtgAAAOAOBTJoxKu09M5ptrIZYgT16H3qWgRBDCIySAM+tT0UUAFRXW3yWLkAD1pLicQr6segrHummm3FySB1HpQBj6gnm3DsvK+pqGC5aCRfMzsGK0fKDAjByTVa6tcjkdaYzZjuFkiDIwKkDtXOa4h/tBgoJAArR0kEq8Lfwjcv9azdcb/AE9segPPagDlvCkQlsGUgEcVsNBG2Ik+U9+OtY/habydPkYDpRPrNz9p2xxqFJ4OM0gNr+y0UfvHY44zjGKuWGmzXJCxsyhDjJrJtri+vS6Atk8kitrT1myI2dwo7ZoEdVpWmLaRqGwTnNahqpbTRiAAEgLxz1pFnQyL5YY5I5xQMtgEE5OahmiMzgOP3eKkZVPUc+tVoYtjBg0nPUZoAltrWOAHYM+9T0gOexpaBBRRRQAUUUUAFFFFACEZqvLC5kBQ4FWaKAM9opTJtduDwKmaENEIiD0q1SHA5NAzmtf0xWgJcAx9/avJdd07y58oQE5y1e5aoiz2zRFiM+hriNQ0CKZWAYs3oR1pgeZjTzvAGWA6E1eFjEFG4bj04NbEujyxSExYUrxgUn2GUhWZHzQBHpSNAmIGYEHO0muy0vU4ziK8iCg4wwHH1rmrLT2Dlzv56mrsSksEDNtHNID0GC0TCyWzI8R/umpzZQzLkLsccbgK5DTNQaxbMchH95Ooaur03VbfUBtQmOXurf0pgWolaHanLA96sUgIHGaWkIKbISFOOtOPApjlcHLADvzQBTaMnLtyc81UfcCeSM1p5j5+Y81DIIwOHbmmMzSuCWxk9qjdSygkc1caJCpO4g/WoSiDo7AUAVrc/ZruOQ8KDhselVvEVru1NmUcFR0q5LFHtI3t0pZoUu9khZgQoU/UUAebeGADprgjqQKtR20f2nBBOVzz2oopCNe0gSNFK5GRnrWi2UEZUnJXJoooA0LFz5G4nJxnmr8MzsgJPaiimMRL2csct/nNTT3EgVSDztzRRQA1buUAqCMfSnJeTYHzDn2oooAuQTu4XcBycVZoopCGuxGMdzik3HaTxxmiigBjysoGMdM0LKxYAgc0UUAUZ7yZJBtIAzjpUEl5Pub56KKYxn9oTn+IUjXszLyRRRQBWluJGVsnpisq5uJQxw3+cUUUAUJM+eTk5NPWZi+3jHSiigAZiBgdCOarEfvduTjGaKKQh6qABgcVYhdtwwSMDtRRQM27e+naHLOSRV+LUZ1XblTj1FFFMBk+pXBjYZXGPSqkl5Njkg0UUMBovJsZyPypPtcvTIoooAU3UnXIpnnvxyKKKQhGncccU5LhwOMUUUDZ/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anteroposterior (AP) view demonstrates tapering of the upper trachea, known as the \"steeple sign\" of croup. Note that the finding can be simulated by differing phases of respiration even in normal children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subglottic edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view demonstrates ballooning of the supralaryngeal structures and marked narrowing of the subglottic trachea secondary to subglottic edema. This finding cannot be simulated in the normal child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39585=[""].join("\n");
var outline_f38_42_39585=null;
var title_f38_42_39586="Normal range of neutrophil counts for preterm infants";
var content_f38_42_39586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Normal range of neutrophil count for newborn infants with a gestational age between 28 and 36 weeks during the first 72 hours of life",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Neutrophils per microL of blood during the first 72 hours after the birth of 28- to 36-week gestation preterm neonates. A total of 8896 values were obtained for the analysis. The 5th percentile, the mean, and the 95th percentile values are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Schmutz N, Henry E, Jopling J, Christensen RD. Expected ranges for blood neutrophil concentrations of neonates: the Manroe and Mouzinho charts revisited. J Perinatol 2008; 28:275.",
"     <a href=\"file://www.nature.com/jp/index.html\" target=\"_blank\">",
"      file://www.nature.com/jp/index.html",
"     </a>",
"     . Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39586=[""].join("\n");
var outline_f38_42_39586=null;
var title_f38_42_39587="Leukocytoclastic vasculitis";
var content_f38_42_39587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78697%7ERHEUM%2F60323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78697%7ERHEUM%2F60323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leucocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leukocytoclastic vasculitis appearing as raised purpura. This lesion can occur with any vasculitic syndrome and in the collagen vascular diseases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drug-induced cutaneous vasculitis with palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 142px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACOANgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDkpLj7OyHG92OFz39f8apXl1KZXSN/MlcCRRvHXjgA8Z96oSajtCLGnmz47LwD7j0NaUKW84WaKGNpEHKc4JPb6ZrxXDl1Z9VTknsdDpNw9xqDu8MYmj+TAcEuSOc+hFXNRukQJDszkjLofukdjzWSq/Z7ZXjULLMNzEZBzjgepqlbXt1ny5ESNmbBuXOTkjuD+VYqPNqdHYnOrzSXe2JG+zk5O4DZjPr696h1QFnsJVlGTk4jbK4+vOeM/wCcUNarvLQSPd2wZQyBsYIPPSn6lHOwjhtSv2ZsFR5ZUgDqPrVaX0Nb6GTd2iW0klyZN2esgP3TyBjnpnFYd7HM/ltJCYsHHHcH/DmtjXEk3SquWKJgL0BUHOSB+VQSr5trDdhlRFZl2Y655zz610U20k2clWHMrHVeCNXa4tVguXy0Q25I5AHQ/SuwBBGQcivGdK1KbStTjmZHRVwJY8HBUn/61etaVeQ3tqskBUqR/Ca61sfPV6fs526F2iinKhJ/xoMhACfepFVjTlQCn0AGKKWiiwBRS8UdKYCc0DJ6Up5FKFJGcUDGc5pTSmjigBtNYt2FPNJSERbmI7Yxmm5bnmp8DsKa2MkZFAWK5JJ5opSADgHNFVG3UD5/srtLrbMN2cAYHUe/1rrNEIeUyFyEwMbh/nFeU6XftaPnJ2N1Fd9omqIEUklsYIYHqKivTdtD0cJiL6M7lLkTXkKRlwyoSVIBHsc1o3Vg17a7JeOQd0WDx34rnY7zDKynf6Jjsfeti31SNA0e2YOMbTg8/iK8yUXHVHrRlcgh02x0u4EDXk0ZbMqRngNkcnPrmp79zDHA7t5hdSjMn3Qpxz60v2uD7WWlty84A2EAncD/ABD6ZNUp4JdRlPzRmAHEhI2hWGcld3cjtT+LVmyvuNBQ2NxFCoXZGeQ2WA9QT7/nmsHU70NMFdAfJYBF24DEg5Ddu+at3kQVc2bO0Eo3IoOCwycj2H60kD2r3KzTxogU5CZ3dBgA8dSf5VtBKOu45Rcl7pnbGdDMfnVl2lWHT5s4H4A/rVa11K809Q0JKw5IAz92txXtL6QwsjxpCx3HzOFBOfmPp7+9RXumxSGaCFk2Mx/dofQjkH8+K0jU5XaSOLE4ZVFdCQeIr9z/AKw1aTXtQPSTisC1jELNGH3AEgZPNaCjgCtmeG1Z2ZqjXb7/AJ6Uv9vX3/PT9TWVj1o2nsDS1CyNb+377+/xSf8ACQX3/PT9TWYI2PbH1pWjCj71K7Cxpf2/fY/1n86D4gvsf6z+dZX4Un6UXA1/+EgvwP8AWfqaQ+IL4/8ALT8s1k0Urgav9vX2f9Z/OkOvX3TzeayjRkUBY1Dr17/z1pp169/57VlFlHbmkyAckH2pjsjSbXr7tKfzqNtdvj/y1OPrWc2PpTDQxWRonWr4/wDLY/nRWaeBzRSCyPJsnFaGm372zqN5C9j6VnUoODmvROaMnF3R6Vp92XizI+GXBXPGfpW5b6hKkKiSJ3ZnH3CSOTj0zXmehao1u3lSOQuRtOfu/wCRXbWt5JiMlla1PBXPJx/X/CuGtRPcwuIU15nUx+dcaSksBbzUmAZSCAV3cg/hUtw2pRKpaNLgM2JDj5UHYY/Hr/jWLZXU5nkhncOCpw4IAz2Jx06c1s20hZ2M9wrqPmHlvkDjpwc/pXJyuLO/muiO6jug8YMPlTbj8xxwuOnHtnvWLJGIiVMYiaM59Sxz+Fdg8UK3cjOIhCVUK+/fuHfI/Lmue1G3jMjiIqxVzyBgge/rW1Jp9BSm3bUbZ3CWtjEsUEe6XJJC7i2MHB9utU2kkmcZMcEsWXYrHj5sjj361cjTypIyAox82RnP/wBbiiHE80rSW+1Q3ybR1Hpj+tXypaiveyKFlA8sczTyLuZ8EgcDv17Ditm2SIKFkQq4AJBqtPbfaWFxD8vkttYEgbvy75781YkkMoUxtJ8oAxtHXnP4cUc9zjr4XmV1uSSCMdFqscZOOlJ5oYn5iOejcGkJ5++AKDy2uV2YtNbpzjNLuH94U19rH7wxRYCJwA1OXGBkClAXOSwpDtxgHHanYVyNsZOOlFOIX+9TTt/vfpSsF0FJgU1tp70h2/3qLDugdT2/Go2Bz1z9Kc23P3jTeD1enYLjfxoI980p29mppYDvTsFwIophkX1oqbMTZ5QeKSr11bFWOKplSK707nM1YQV02h6gJY1gmOHX7rd8VzQFSRu0Tq6HDA5BpSVzSlNwd0erLPY3VmvmPIsztnHrjjp27Vb047VDwEO44ZzkhgfX071zWhTrNbJMoJVwVI9CP6/zrpz5SKZopkkB6xsMMOo9q4pRUHZ7HuUqrqxvEltlbaqtEQR8o2juO2K0rW2E90zhVSdcEg89QOOfpVN71gGeQbWXG38uQarxao5kVbRU3jIG7gDp1zVJSloRKXL7x0a6dHPMkW4xSTuE34ByeOf0FF/pEtikkThmkBIRlOM5H9elUbfXbtWVWiZpNvMkYB2NnryeR/nmt611y4it7bfaGV3J+b7zOcj5sDgCueXPB3R1QmpxszmJYBZsIxmN3O4JnLMexz+tVBC8TSJGJPnUblDY/wA//XrsdXt4niWad4mkIz+6wPUD34/X8q5C6ikMiujZUjJI47nj60Rlzam6s9AuIwZImVkdFTkg4x7VUMqliOgzx6Vaa22RlBkYb+L0qpJCqJvDYz37j61pF6WOPE4ZTd0ibYewz9KQoR1rNinmiYmPgYyQRxV631KKUFZRsYdSOVpyjJbHnSpcu47aaNpq2Cr8jBHrS4BHTisXJk8qKLKx6YpNjY6irjIuRxTCg7A0c7DkRU8k0CI1cEfrTWXBo52VyorGE47UwR5OKtkCjaM570c7DkRT8naAAMAU1oc1eKg00jmjnYOCXQzzBjoaKtumeRRVKT7i5TjLqz3dB+FYl3ZlSeK7Ex5H3eDVS6stwOFrpjOxzuNziXQoeabWze2RUnisx4SDXQpJmbVjqPA8vmedbHqn7xTjt0I/UV2sVsrQPlDvzk5bgfXH1rgfBJWPWQXcINh69+RxXq0fnhC2+PazbT8pBOPXB6c9DWNSz3OzCymvhM+4s5toV9pjVcIcjjOeOayLSxu47omRzGn+0xUfpmupjSRwMyyMpHIIXn/OaY8SRq+4MYxn5j2AHcn1NQm1qjtsnoyv8gkV4hGGXBCqckY7k8ZzVqwlYzkBwCTkAMF7gkk9fyptpFbsA0bgFjgKpzn646dqvWu4ExiP5Q2SCMgHPap5ru7Go8isSGZvKLStvAwN4P3eoABxWZHZSJI7AByXLHGcH8z1q9Ikjb0cnywcKuBx3+pNSlisCodxBbd8gzj6Dv8AWk46aG1OrZlS6t440b5TtzjIycH0rMmVo1BbBRl+72z9Poa15y3zLkhQRkkcg/5NVpoAYm2u23JAbHf04rJKx1qaZzl8gG1tnLHJI/Os+RTncvDE7fQGt2eBy2wIO3Ht7fjVTyPLkZGjyOxwOO+K6I6I5ZwTZTgd7bDxykEkfIASK0INSVXKXI2ejfwn/CqjQuHDQhsMeF6Z+lPVnYeTcRqYwe/f2z/jUzSerMJYZPbQ1wVkXKkFSMgilxWMn2iwZAqbUc4CHlTzxg1oWt/DOxTOyTONrHBP09a53DqjnqUpQdmWSKTaOc1IV4oK96gzsyEoM5pu3PSp9vpSbDnjikPUgKkUlWNnFRmM9sUXGREUU/y26GimiXYwaXaW4xmn7e1SCPB68V0GNjMu7MSLkLzXOX1ntYkCu52g8Vkanaj5uKuE2iXG5z/hlJP7ZjVFQtg8OMivTLKZoxMitGWYckjOP88VyPg7THn1iSVF4jXH1JP+FehrpdwuAoVHI/uk5qqs47M7MFTlukR224uC8kgPqOMmtGS1jm83cqlWTBY5zWTPZTR4SV2jI+YBRjjNSo6hiRKcpztzndUp3R1ypu9y3BZW0WSW+8wOSc9OlWJWgUM7Zd2OB8o4981SWUMMFVOBk7f0FSPsRVabMas4UbjwTTJat8Q+aUBujojDnA6gegqrBcZk3BiUDAbj/D7CrhMMsgR9rbeNwYE59KbPtTKeWflyAq8fmaq66jUW/hRGGQyOzu3zAgE9M/T196oIkoZozLiIfMJOhzn9aZczyEkKvPovt6UgjmBWOXdtIyFBqbot05LVkirFG2d+1RyAO+fanNbJOcwjHZQR096glVWuAm4kqcA+vX+lSo+DGc+WxOGHrSe5tFxa90ZLbIzRFzudVIyx56mq6wkKJZFVtuATg9+/8hWuiIgy3O4g4agRxOkjMVRmPygdD7CspysdVKKerMK/TzJYAoTA+7FkqYz2/Ws69t/LZt0Yz3KYO0/411UtuZHO5Pl655PQds/54qK405JWVyu1TgYIwB9f896yU+U1nTjURzUep3VsiidBKD0JOCPx71MmsMZNnlKfYE1t3mjQyEDZhlAA255+prAvLNrdQXjw4HBxnP8AjWlOdOfQ8qvgpQ1jsX01KFiAUlQn+8vvirsbrKPkbIrmL0IyqZY1VzjkHHA9BVnTpQY12TtleOSckdquVGLXunJ7KS3OhCetNZcVRtb26Enl3EG7/bQ/0NaClZUDIQVPQ1zyi4vUzalHcjIopzAetFCE9TCA4ApQOvNFOUc8Vuc6AVW1BcoDV5V45qC+UCKknqUL4Rl8kTYHLSf0ru7N3kifYWJPKgHn3rzPRbxLbU/Ll+6/T616GsuBEUJUAYDCprxbPTwFRKNiSa1uJp1Y85yAp4KjNQnTUV2VlJIB6NWsTK8AKklj/FnqPSr0G0gGRB8oxjHBqIuyPQdS2qOa/s1llYq5wBwvtx/jUrLshDzRYHOwjofr71ukxyM7F1DIcDHGB6Vi6hPM9wkaqsiZwo7j3rRTexzzipO7GmZXkjkgUkMOuOn09KrvI6xSDLKT6moysizbjkKp5wMVn6heJDEd8jYXsxzVJtkucI9SWa4jjZNxOVUY44Hr+tQNqcak5IcNn73JrnJ9SXcTLJhD0Gc1VXU4PNVsD5fetFBnNLExvvc6h9YUSbljRAVKjIyc02C6GAt0QXZvlY89e1c9LqC3M28EDt8uAD+FRR3XzlWZgwORg4qlEqOIjay0O7hCqMSN+7ccsEJx/k4qUSM3krLEoQHCtu5YelcvY648IMaE4A7jOa0re+W6cuwYSOeBnAz+VYzg76nXSrprQ6hFiaQrl3TO1sLwp989+nNWoLCGZEdV3fPn733QR0PrWa9yZLWOKOTYRwWI4b61djkEe4cKrYOQ3euZ7HUpX1RoTWW0qpO0E45Uc565/wAaxNT0p5VG0nhiR7GrI1zLSK672RsADkH3pn9stIz7UUE8DPSo5Lao0UpLc5K/0x4/lcSMxxhm6/Tj3osdJVGYmIovCqFAPPJ7V2KXttLty8Zxyw2n1qSB7Dy28s9WPvWnPNKxk/ZvVo4C7NxpE8cyIsij5XR/Q961bexmhupXTBjmwwjGSF47Vd1u0jmYMSQp9e9Fvq8+l2qxxSRvGmMbl547ZrVvnjZbnn16LT93VFWVChwwwfQ0U+W8OoO10VCCToufSisl5nC9HYwdvTFSLzxjmlAxn0pyqD1FbbnOOVcE1U1EgR81dFUtSX5M+1C3G9ji9UmKy7kJDKcg11vhzxCb2BYpZNsqgZHvmuL1cHzG471RhYrzkg9iK7ORSiZQqypSuj3e21Vo0jVj83Y9ea0pNT+UrGQfU56V4JHqF3GMJcSgem7NTrrWoL0uXFYuh2OtY3uj2W81CKCP5jgn35+tY93r9lbFnD5bHU9QK8sm1G7lJMlxIfxqAyM/3mJPuaSod2N42+yO21Hxe8hcQMzA8egrmbvULm7YmaQn2HSqGcHinAgDOeTWkYKOxzVKkp7khJJopgbJp2adzGw4HFLvYHIJ/Om0madwuWVuJFOQ5q5baxNCuOuOntWXRQ7PctVJR2Z1EHiZ12b8nufrWhH4lhKohfD8Yrh80Vm6cWdUMfVieif2vERlplLY7Vn3HiCON2USYGOgFcZmgnNJU4ouWYVGtDoLnxFMYikBIYn7/pTrLxPdQ8S4b3UYNc5mlz71fKjm+sTve513/CSz3bhFIAHA3Vs2MaTovnuZOc4xgV50kjI2R1rotE1OXcATkCspw0900WIlPRs7UADgAYoqvaTeagz1orls0BnhvSnr9ajBPIp4FaGaJFwevSmXMIlTHpThU0ZJUU7lM4TXbJgzHFc7ja2K9Q1GxSdSD1Iri9W0jyGLK49a6qVRPRmFSHVGOvSlpShQ4JBNAGcCtTJBRVq3snmOAyit3T/DgkKtJKPwqZTUdy1Fs56GCSRsKpz9K2bLw9cXHUFR7iuz0/QoLcA8EitiONIx8oxxXNOv2NVC25xkPg8kAvLg/SpH8HDbkTH8q7NTkCmkgnHOM1l7aRXKjh5fCEoHyy/pVGfw1dxZ24b6CvRnBxkHmk2DGfamq8g5EeUT2FzAfnib8qqMGViGUg167JbRyfKyg+vFULrQLS4PK4JrRV11RPs+x5cTjml3du9dzceE7djlJCprOl8KFclZxx7VoqsWLkZy5PA+tAJ7cmuhXwu2eZ1x9DWpY+F4VPzyZ70OpFByM40q2PukmjBHUEV6ZFolokf3M4px0KykGWjrP26H7I8yVGY4AJ/Ct7RLCXeGKkfhXZRaJaIAVjAq0tukanYAMVMq91oVGnbcrWMJijwetFWGOBk9qKyLbP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dense palpable purpura on the lower extremity of a patient with drug-induced cutaneous vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leonard Calabrese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39587=[""].join("\n");
var outline_f38_42_39587=null;
var title_f38_42_39588="Erythroplakia";
var content_f38_42_39588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Erythroplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A red patch is present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Carl Allen, DDS, MSD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39588=[""].join("\n");
var outline_f38_42_39588=null;
var title_f38_42_39589="Tranylcypromine: Patient drug information";
var content_f38_42_39589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tranylcypromine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32215?source=see_link\">",
"     see \"Tranylcypromine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Parnate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Parnate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression). It is most often given after other drugs have failed to help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tranylcypromine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Headaches, liver disease, pheochromocytoma, very weak heart, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you cannot follow the diet needed when taking this drug. See How Is This Drug Best Taken? for more details.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use OTC drugs that have dextromethorphan or pseudoephedrine. They may cause very high blood pressure when used with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of caffeine (for example, tea, coffee, cola) and chocolate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid eating foods like aged cheeses and meats, soy sauce, soy beans, Miso soup, Italian green beans (fava beans), snowpea or broad bean pods, sauerkraut, kimchee, yeast extracts (Marmite), red or white wine, and beer including alcohol-free beer. Very bad side effects may happen. Ask your doctor for a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped, follow diet for at least 2 more weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11113 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-0E46A87C69-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39589=[""].join("\n");
var outline_f38_42_39589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229991\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229992\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030790\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030792\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030791\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030796\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030797\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030799\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030794\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030795\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030800\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030801\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32215?source=related_link\">",
"      Tranylcypromine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_42_39590="Anatomy and development of the teeth";
var content_f38_42_39590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomy and development of the teeth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     J Tim Wright, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     Ann Griffen, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39590/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/42/39590/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The close relationship among oral, systemic, and psychologic health requires that oral health be evaluated thoroughly as part of health maintenance supervision. An understanding of the normal sequence and patterns of tooth eruption is the foundation for identifying and treating children with abnormal dental development and optimizing their oral health.",
"   </p>",
"   <p>",
"    The normal anatomy and development of human dentition are reviewed here. Problems in dental development and syndromes associated with abnormal dental development are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=see_link\">",
"     \"Developmental defects of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental development proceeds from approximately the sixth week in utero through late adolescence. It involves the formation, eruption, and shedding of the 20 primary (deciduous or shedding) teeth, as well as the formation and eruption of the 32 permanent teeth. Throughout this prolonged span of development, the teeth are subject to both genetic and environmental influence. The timing, location, morphology, structure, and composition of teeth primarily are genetically controlled and are regulated by hundreds of genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DENTAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their role in speech and facial aesthetics, the teeth provide an efficient system of mastication with incising, tearing, and grinding capabilities. The unique composition and structure of teeth allow them to survive the forces and wear of mastication; alteration of the composition or structure of the teeth affects their durability, resistance to fracture, and retention in the oral cavity.",
"   </p>",
"   <p>",
"    Each tooth has a visible crown that projects above the gingiva (gum), with one or more roots extending into the alveolar bone of the maxilla or mandible (",
"    <a class=\"graphic graphic_figure graphicRef75679 \" href=\"mobipreview.htm?0/37/599\">",
"     figure 1",
"    </a>",
"    ). The crown and root meet at the neck of the tooth. The tooth forms a peg and socket joint with the alveolar bone and is held in place by the periodontal membrane that allows slight movement of the tooth.",
"   </p>",
"   <p>",
"    Four components of teeth are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enamel",
"     </li>",
"     <li>",
"      Dentin",
"     </li>",
"     <li>",
"      Pulp",
"     </li>",
"     <li>",
"      Cementum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Enamel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental enamel is the hardest tissue in the human body; it protects the tooth crown from fracture and wear. The enamel is produced by ameloblasts that secrete, process, and control the mineralization of the unique extracellular matrix. The ameloblasts protect the formed enamel during tooth eruption and then become part of the epithelial attachment of the tooth to the gum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/2\">",
"     2",
"    </a>",
"    ]. Because the ameloblasts are no longer present once the tooth is fully formed and erupted, dental enamel has no regenerative capacity.",
"   </p>",
"   <p>",
"    By weight, normal dental enamel is 96 percent mineral, 2 percent water, 1 percent protein, and 1 percent other components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/3\">",
"     3",
"    </a>",
"    ]. Mineralization occurs through the tightly controlled processing of the extracellular matrix and regulation of calcium and phosphate mineral deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/4\">",
"     4",
"    </a>",
"    ]. Fully developed enamel consists primarily of carbonate-substituted hydroxyapatite molecules that are organized into crystallites and arranged into interlocking prisms (",
"    <a class=\"graphic graphic_picture graphicRef74565 \" href=\"mobipreview.htm?6/16/6403\">",
"     picture 1",
"    </a>",
"    ). The structure of enamel provides its strength and resistance while making it less brittle.",
"   </p>",
"   <p>",
"    Changes in the mineral, water, or protein content of enamel alter its appearance, strength, and resistance to wear and caries. As an example, substitution of fluorine for carbonate decreases the acid solubility of the enamel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentin is the most abundant dental tissue. It functions as the substructure for the enamel and largely determines the size and shape of teeth. Dentin is produced by the dental pulp. The production of dentin is increased in response to environmental stimuli such as trauma, tooth wear, or caries; reparative dentin is then deposited along the pulpal wall to protect the pulp from injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By weight, dentin contains about 60 percent mineral and 20 percent organic components, including protein. Type I collagen is the predominant dentin protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/7\">",
"     7",
"    </a>",
"    ] and interacts with noncollagenous proteins to initiate and regulate mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dentin is composed of a complex organization of tubules (",
"    <a class=\"graphic graphic_picture graphicRef68204 \" href=\"mobipreview.htm?1/10/1187\">",
"     picture 2",
"    </a>",
"    ) that are filled with fluid or the cellular processes of the odontoblasts and are thought to have a role in the neurosensory function of teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/7\">",
"     7",
"    </a>",
"    ]. The structure and composition of dentin impart teeth with the ability to flex and absorb tremendous functional loads without fracturing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dental pulp is a specialized tissue made of odontoblasts (dentin-producing cells), fibroblasts, blood vessels, nerves, and a complex extracellular matrix. It provides the neurosensory function and reparative potential of teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulp continues to produce small amounts of dentin throughout the life of a tooth as part of normal pulp physiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/10\">",
"     10",
"    </a>",
"    ]. Maintaining a healthy dental pulp until the root of the tooth is fully formed and has walls thick enough to sustain the forces transmitted from the crown during mastication is important. The prognosis for successful endodontic treatment and tooth retention is diminished if the pulp becomes nonvital in a tooth that lacks complete root formation, although pulp tissue in young teeth with incomplete closure of the apex can be regenerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, prompt and appropriate treatment of dental trauma and caries in children is critical to the sustenance of oral health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cementum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cementum is made of type I and other collagens, noncollagenous proteins, and a mineralized matrix. It covers the root surface and helps to prevent the tooth from becoming fused to or resorbed by the adjacent alveolar bone. It is structurally similar to bone, with cementocytes lying in lacunae and interconnected by canaliculi. In addition, cementum provides the tissues by which the tooth is anchored to the periodontal ligament and the alveolar bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/12\">",
"     12",
"    </a>",
"    ]. The cementum, periodontal ligament, and alveolar bone comprise a flexible sling that holds the tooth in place while allowing the physiologic movement necessary under the forces required for chewing. All three of these tissues have some capacity to regenerate, allowing traumatized teeth (eg, tooth avulsion) or pathologic conditions (eg, periodontal disease) to be treated successfully in many cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DENTAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early embryonic requirements for dental development are differentiation of the oral ectoderm and migration of neural crest cells into the craniofacial region where the tooth buds will ultimately form. Dental development begins at approximately the sixth week in utero, when the oral ectoderm starts to proliferate at the future sites of primary teeth. As the oral ectoderm proliferates, it forms nests in the underlying mesenchyme and eventually contacts and interacts with the neural crest-derived ecto-mesenchymal cells, initiating the development of the tooth bud primordia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These early events in tooth development are regulated by the oral epithelium and require the expression of numerous genes including transcription and growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Teeth do not develop, for example, in transgenic mice that are missing the transcription factors MSX1 and MSX2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction between the ectodermal cells and the underlying ecto-mesenchymal cells leads to differentiation of the highly specialized cells that produce the dental tissues and establish the tooth size and shape. The location and tooth type (eg, incisor, cuspid, premolar, molar) are thought to be genetically determined through the differential expression of transcription factors in the regions of the developing teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/17\">",
"     17",
"    </a>",
"    ]. The ameloblasts or enamel-forming cells are derived from the oral epithelium; the odontoblasts that form dentin and pulp are derived from the ectomesenchymal cells; the cementoblasts are derived from the mesenchyme. For an intact and viable tooth to develop, each of these cell types must differentiate, produce, and process the extracellular matrix and regulate mineralization of the extracellular matrix.",
"   </p>",
"   <p>",
"    Each of these steps is under strict genetic control and represents a potential pathway for a hereditary defect of dental development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=see_link\">",
"     \"Developmental defects of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TOOTH ERUPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process by which teeth emerge from their developmental crypt into the oral cavity is known as tooth eruption. It involves both the teeth and the tissues through which the emerging teeth pass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary teeth eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eruption of teeth typically is bilaterally symmetric, with the left and right teeth appearing at similar times. The mandibular central incisors are the first primary teeth to erupt, usually between 6 and 10 months of age (",
"    <a class=\"graphic graphic_figure graphicRef51028 \" href=\"mobipreview.htm?41/33/42525\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/20\">",
"     20",
"    </a>",
"    ]. The maxillary central incisors erupt next, followed by the lateral incisors, first molars, canines, and second molars, in sequential order. In general, the primary dentition is fully erupted by 30 months of age. By convention in the United States, general dentists identify the primary teeth by the letters A through T (",
"    <a class=\"graphic graphic_figure graphicRef62142 \" href=\"mobipreview.htm?19/42/20128\">",
"     figure 3",
"    </a>",
"    ). Different identification systems are used in other countries. Variability in the timing and sequence of tooth eruption is to be expected for both primary and permanent teeth. Gender and",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    affect the timing of tooth eruption; girls tend to develop their teeth earlier than do boys, and black children earlier than whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Teething symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is normal for infants whose primary teeth are erupting to be cranky, chew on objects, and have excessive drooling. Parents frequently report that their infants who are teething have fever, diarrhea, or other systemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, evaluation for other causes should be performed before severe signs and symptoms are attributed to teething [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/28\">",
"     28",
"    </a>",
"    ]. This is supported by an observational study in which all but 2 of 50 children who were admitted to the hospital with an initial complaint of teething were diagnosed with a medical condition (including bacterial meningitis in one child) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, a systematic review of prospective cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/25,27,30\">",
"     25,27,30",
"    </a>",
"    ] found no symptoms, signs, or clusters of symptoms and signs specific enough to teething to reliably exclude other clinically important conditions (eg, infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/31\">",
"     31",
"    </a>",
"    ]. In a subsequent prospective study of infants (5 to 15 months of age) with daily data collection, the most frequent signs and symptoms of primary tooth eruption were parent-reported irritability, increased salivation, and loss of appetite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/28\">",
"     28",
"    </a>",
"    ]. The mean increase in temperature on the day of eruption compared with noneruption days was minor (0.12 and 0.01&deg;C, for tympanic and axillary temperatures, respectively).",
"   </p>",
"   <p>",
"    The management of teething symptoms is palliative (eg, chewing on a chilled teething ring or other teething device, oral analgesia). To prevent choking, teething rings and other chewing devices should be one piece. To prevent promotion of dental caries, these devices should not be dipped in sugary substances. The benefit of topical gels in managing teething pain has not been demonstrated. Methemoglobinemia has been reported in association with the use of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    sprays; benzocaine-containing teething gels should not be used in teething infants or children younger than two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H44#H44\">",
"     \"Topical anesthetics in children\", section on 'Benzocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary tooth exfoliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary tooth exfoliation occurs as part of the process of permanent tooth eruption, which usually begins at approximately six years of age (",
"    <a class=\"graphic graphic_figure graphicRef58400 \" href=\"mobipreview.htm?8/34/8750\">",
"     figure 4",
"    </a>",
"    ). The permanent tooth, which develops apical to the primary tooth, helps stimulate resorption of the primary tooth root as it migrates through the alveolar bone toward the oral cavity. As the permanent tooth nears the mucosal surface, most of the root of the primary tooth has been resorbed; the primary tooth begins to loosen and eventually falls out. Primary teeth lacking a permanent successor typically undergo root resorption and ultimately exfoliate, indicating genetic programming for root resorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Early exfoliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature exfoliation of primary teeth (before the age of four years) can be caused by local factors or systemic health problems, some of which are life threatening (",
"    <a class=\"graphic graphic_table graphicRef58443 \" href=\"mobipreview.htm?22/34/23084\">",
"     table 1",
"    </a>",
"    ). A thorough medical evaluation and referral to a pediatric dentist are indicated in cases of premature primary tooth exfoliation so that optimal and appropriate treatment, if necessary or available, can be initiated promptly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=see_link\">",
"     \"Developmental defects of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Delayed exfoliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over-retention of the primary tooth can occur if during permanent tooth eruption the primary tooth root does not adequately resorb. As a consequence, the permanent tooth will often emerge ectopically (out of its normal position). Ectopic eruption of permanent teeth frequently occurs in the anterior region of the mandible, where the permanent teeth come in on the tongue side of the primary teeth (",
"    <a class=\"graphic graphic_picture graphicRef62027 \" href=\"mobipreview.htm?16/29/16848\">",
"     picture 3",
"    </a>",
"    ). In most cases, the primary tooth will exfoliate within one year without treatment; however, extraction occasionally is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Permanent teeth eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent teeth usually begin to erupt at six years of age (",
"    <a class=\"graphic graphic_figure graphicRef58400 \" href=\"mobipreview.htm?8/34/8750\">",
"     figure 4",
"    </a>",
"    ). They enter the oral cavity when approximately two-thirds of the root is formed. Once permanent teeth have penetrated the oral soft tissue, they erupt at a rapid rate, continuing to emerge until they make contact with teeth or tissue in the opposing arch. Over-eruption of a new tooth can occur if opposition is lacking because of missing or malaligned teeth. The central incisors and first molars are the first permanent teeth to erupt, followed sequentially by the lateral incisors, canines, first premolars, second premolars, second molars, and third molars. By convention in the United States, general dentists identify the permanent teeth by the numbers 1 through 32 (",
"    <a class=\"graphic graphic_figure graphicRef82290 \" href=\"mobipreview.htm?25/40/26241\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Delayed eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children whose primary or permanent teeth erupt six months or later than normal, or who have asymmetric eruption, should be evaluated for abnormal dental eruption or congenitally missing teeth. Delays in dental eruption can be familial or can occur with conditions such as Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/34\">",
"     34",
"    </a>",
"    ], hypothyroidism, hypopituitarism, achondroplastic dwarfism, osteopetrosis, rickets, or chondroectodermal dysplasia.",
"   </p>",
"   <p>",
"    Complete failure of tooth eruption can occur for a variety of reasons, the most common being a lack of space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/35\">",
"     35",
"    </a>",
"    ]. Complete failure of tooth eruption also is associated with a variety of conditions and syndromes (eg, Albright hereditary osteodystrophy, ectodermal dysplasias, William syndrome, oto-palatal-digital syndrome [Taybi syndrome]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=see_link\">",
"     \"Developmental defects of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Accelerated eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated eruption of the primary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    permanent teeth can occur in a variety of conditions, including preterm birth, various syndromes, and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Accelerated dental eruption of the mixed dentition can occur in children for a variety of reasons, including dental caries in the primary dentition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/42\">",
"     42",
"    </a>",
"    ] and diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Dental maturity is accelerated in patients with Turner syndrome, but the timing of clinical eruption is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39590/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dental development proceeds from approximately the sixth week in utero through late adolescence. It involves the formation, eruption, and shedding of the 20 primary teeth, and the formation and eruption of the 32 permanent teeth. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eruption of teeth typically is bilaterally symmetric, with the left and right teeth appearing at similar times. The mandibular central incisors are the first primary teeth to erupt, usually between 6 and 10 months of age (",
"      <a class=\"graphic graphic_figure graphicRef51028 \" href=\"mobipreview.htm?41/33/42525\">",
"       figure 2",
"      </a>",
"      ). The primary dentition usually is fully erupted by 30 months of age. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Primary teeth eruption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of teething include fussiness, mouthing behaviors, and drooling. Parents frequently report systemic symptoms (fever, diarrhea) associated with teething. These symptoms are not specific enough to teething to reliably exclude other clinically important conditions (eg, infection). The management of teething symptoms is palliative. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Teething symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary tooth exfoliation occurs as part of the process of permanent tooth eruption, which usually begins at approximately six years of age (",
"      <a class=\"graphic graphic_figure graphicRef58400 \" href=\"mobipreview.htm?8/34/8750\">",
"       figure 4",
"      </a>",
"      ). Premature exfoliation of primary teeth can be caused by local factors or systemic health problems, some of which are life threatening (",
"      <a class=\"graphic graphic_table graphicRef58443 \" href=\"mobipreview.htm?22/34/23084\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary tooth exfoliation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Permanent teeth usually begin to erupt at six years of age (",
"      <a class=\"graphic graphic_figure graphicRef58400 \" href=\"mobipreview.htm?8/34/8750\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Permanent teeth eruption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children whose teeth erupt six months or later than normal, or who have asymmetric eruption, should be evaluated for abnormal dental eruption, congenitally missing teeth, and various systemic conditions (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Delayed eruption'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/1\">",
"      Maas R, Bei M. The genetic control of early tooth development. Crit Rev Oral Biol Med 1997; 8:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/2\">",
"      Simmer JP, Fincham AG. Molecular mechanisms of dental enamel formation. Crit Rev Oral Biol Med 1995; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/3\">",
"      Robinson C, Weatherell JA, Hallsworth AS. Variatoon in composition of dental enamel within thin ground tooth sections. Caries Res 1971; 5:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/4\">",
"      Robinson C, Fuchs P, Deutsch D, Weatherell JA. Four chemically distinct stages in developing enamel from bovine incisor teeth. Caries Res 1978; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/5\">",
"      Weatherell JA, Deutsch D, Robinson C, Hallsworth AS. Fluoride concentrations in developing enamel. Nature 1975; 256:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/6\">",
"      Tziafas D. Basic mechanisms of cytodifferentiation and dentinogenesis during dental pulp repair. Int J Dev Biol 1995; 39:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/7\">",
"      Linde A, Goldberg M. Dentinogenesis. Crit Rev Oral Biol Med 1993; 4:679.",
"     </a>",
"    </li>",
"    <li>",
"     Butler WT, Ritchie HH, Bronckers AL. Extracellular matrix proteins of dentine. In: Dental enamel, John Wiley &amp; Sons, Chichester, UK 1997. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/9\">",
"      Pashley DH. Dynamics of the pulpo-dentin complex. Crit Rev Oral Biol Med 1996; 7:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/10\">",
"      Solheim T. Amount of secondary dentin as an indicator of age. Scand J Dent Res 1992; 100:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/11\">",
"      Jung IY, Lee SJ, Hargreaves KM. Biologically based treatment of immature permanent teeth with pulpal necrosis: a case series. J Endod 2008; 34:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/12\">",
"      Yamamoto T, Hinrichsen KV. The development of cellular cementum in rat molars, with special reference to the fiber arrangement. Anat Embryol (Berl) 1993; 188:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/13\">",
"      Ripamonti U, Reddi AH. Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Crit Rev Oral Biol Med 1997; 8:154.",
"     </a>",
"    </li>",
"    <li>",
"     Thesleff I, Aberg T. Tooth morphogenesis and differentiation of ameloblasts. In: Dental enamel, John Wiley &amp; Sons, Chichester, UK 1997. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/15\">",
"      Thesleff I. Homeobox genes and growth factors in regulation of craniofacial and tooth morphogenesis. Acta Odontol Scand 1995; 53:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/16\">",
"      Thesleff I, Nieminen P. Tooth morphogenesis and cell differentiation. Curr Opin Cell Biol 1996; 8:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/17\">",
"      Sharpe PT. Homeobox genes and orofacial development. Connect Tissue Res 1995; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/18\">",
"      Marks SC Jr. The basic and applied biology of tooth eruption. Connect Tissue Res 1995; 32:149.",
"     </a>",
"    </li>",
"    <li>",
"     Wise GE. Cell and molecular biology of tooth eruption. In: The biological mechanisms of tooth eruption, resorption and replacement by dental implant, Davidovitch Z (Ed), EBSCO Media, Birmingham, AL 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/20\">",
"      Lunt RC, Law DB. A review of the chronology of eruption of deciduous teeth. J Am Dent Assoc 1974; 89:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/21\">",
"      Demirjian A, Levesque GY. Sexual differences in dental development and prediction of emergence. J Dent Res 1980; 59:1110.",
"     </a>",
"    </li>",
"    <li>",
"     Dixon GH, Stewart RE. Genetic aspects of anomalous tooth development. In: Oral Facial Genetics, Stewart RE, Prescott GE (Eds), CV Mosby Company, St. Louis 1976. p.124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/23\">",
"      Wake M, Hesketh K, Allen M. Parent beliefs about infant teething: a survey of Australian parents. J Paediatr Child Health 1999; 35:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/24\">",
"      King DL. Teething revisited. Pediatr Dent 1994; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/25\">",
"      Wake M, Hesketh K, Lucas J. Teething and tooth eruption in infants: A cohort study. Pediatrics 2000; 106:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/26\">",
"      Wake M, Hesketh K. Teething symptoms: cross sectional survey of five groups of child health professionals. BMJ 2002; 325:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/27\">",
"      Macknin ML, Piedmonte M, Jacobs J, Skibinski C. Symptoms associated with infant teething: a prospective study. Pediatrics 2000; 105:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/28\">",
"      Ramos-Jorge J, Pordeus IA, Ramos-Jorge ML, Paiva SM. Prospective longitudinal study of signs and symptoms associated with primary tooth eruption. Pediatrics 2011; 128:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/29\">",
"      Swann IL. Teething complications, a persisting misconception. Postgrad Med J 1979; 55:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/30\">",
"      Jaber L, Cohen IJ, Mor A. Fever associated with teething. Arch Dis Child 1992; 67:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/31\">",
"      Tighe M, Roe MF. Does a teething child need serious illness excluding? Arch Dis Child 2007; 92:266.",
"     </a>",
"    </li>",
"    <li>",
"     Questions &amp; Answers: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth www.fda.gov/Drugs/DrugSafety/ucm250029.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     FDA Consumer Updates. Benzocaine and Babies: Not a Good Mix. Available at: www.fda.gov/ForConsumers/ConsumerUpdates/ucm306062.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/34\">",
"      COHEN MM, WINER RA. DENTAL AND FACIAL CHARACTERISTICS IN DOWN'S SYNDROME (MONGOLISM). J Dent Res 1965; 44:SUPPL:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/35\">",
"      Bedoya MM, Park JH. A review of the diagnosis and management of impacted maxillary canines. J Am Dent Assoc 2009; 140:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/36\">",
"      Rasmussen P, Kotsaki A. Inherited primary failure of eruption in the primary dentition: report of five cases. ASDC J Dent Child 1997; 64:43.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Appendix I: Pattern of malformation differential diagnosis by anomalies. In: Smith's Recognizable patterns of Human Malformation, 6th ed, Saunders, Philadelphia 2006. p.894.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/38\">",
"      Harila-Kaera V, Heikkinen T, Alvesalo L. The eruption of permanent incisors and first molars in prematurely born children. Eur J Orthod 2003; 25:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/39\">",
"      Pinheiro M, Snel AL, Freire-Maia N. Odontomicronychial ectodermal dysplasia. J Med Genet 1996; 33:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/40\">",
"      Aldred MJ, Crawford PJ, Chadwick BL, et al. Precocious tooth eruption and loss in Letterer-Siwe disease. Br Dent J 1988; 165:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/41\">",
"      Hilgers KK, Akridge M, Scheetz JP, Kinane DE. Childhood obesity and dental development. Pediatr Dent 2006; 28:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/42\">",
"      Leroy R, Bogaerts K, Lesaffre E, Declerck D. The effect of fluorides and caries in primary teeth on permanent tooth emergence. Community Dent Oral Epidemiol 2003; 31:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/43\">",
"      Lal S, Cheng B, Kaplan S, et al. Accelerated tooth eruption in children with diabetes mellitus. Pediatrics 2008; 121:e1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/44\">",
"      Boh&aacute;tka L, Wegner H, Adler P. Parameters of the mixed dentition in diabetic children. J Dent Res 1973; 52:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39590/abstract/45\">",
"      Midtb&oslash; M, Halse A. Skeletal maturity, dental maturity, and eruption in young patients with Turner syndrome. Acta Odontol Scand 1992; 50:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6283 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39590=[""].join("\n");
var outline_f38_42_39590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DENTAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Enamel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cementum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DENTAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TOOTH ERUPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary teeth eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Teething symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary tooth exfoliation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Early exfoliation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Delayed exfoliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Permanent teeth eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Delayed eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Accelerated eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6283|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/37/599\" title=\"figure 1\">",
"      Structure of the tooth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/33/42525\" title=\"figure 2\">",
"      Normal primary tooth eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/42/20128\" title=\"figure 3\">",
"      Primary teeth identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/34/8750\" title=\"figure 4\">",
"      Normal permanent tooth eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/40/26241\" title=\"figure 5\">",
"      Permanent teeth identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6283|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/16/6403\" title=\"picture 1\">",
"      Prismatic structure of enamel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/10/1187\" title=\"picture 2\">",
"      Dentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/29/16848\" title=\"picture 3\">",
"      Lingual mandibular incisors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6283|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/34/23084\" title=\"table 1\">",
"      Early primary tooth loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_42_39591="Hamilton-Norwood scale for male androgenetic alopecia";
var content_f38_42_39591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Hamilton-Norwood scale for male androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 711px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39591=[""].join("\n");
var outline_f38_42_39591=null;
var title_f38_42_39592="Nonendem Burkitt NHL Light";
var content_f38_42_39592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonendemic (sporadic) Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of nonendemic Burkitt non-Hodgkin's lymphoma shows sheets of small, undifferentiated cells with interspersed tingible-body macrophages (starry-sky pattern) (arrows, 400x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39592=[""].join("\n");
var outline_f38_42_39592=null;
var title_f38_42_39593="Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis";
var content_f38_42_39593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Sherine E Gabriel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Cynthia S Crowson, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39593/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/42/39593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a common disorder that may have plagued ancient people, although it has been recognized with increased frequency in more recent centuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/1\">",
"     1",
"    </a>",
"    ]. In the mid-nineteenth century, Garrod was the first to distinguish RA from gout and rheumatic fever. Following four decades (1955 to 1994) of decline, the incidence of RA appears to be increasing in recent years (1995 to 2007) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of RA is not known, but many possible etiologies have been identified. Important etiologic clues have been suggested by the identification of unique features of populations with a predilection for RA. As an example, the observation of geographic clustering of the disorder in ancient skeletons implies an important role for environmental factors, which are still poorly defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to environmental factors, hormonal, genetic, infectious, and other variables also contribute to RA in some manner.",
"   </p>",
"   <p>",
"    Multiple different factors probably interact in genetically susceptible hosts to initiate polyarticular synovitis. Once started, the process ultimately becomes self-perpetuating. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, risk factors for, and possible causes of rheumatoid arthritis will be reviewed here. The pathogenesis of the synovitis in this disorder, including the roles of T cells, B cells, and cytokines, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of RA has been reported to be around 40 per 100,000. The disease prevalence is about 1 percent in Caucasians but varies between 0.1 percent (in rural Africans) and 5 percent (in Pima, Blackfeet, and Chippewa Indians) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Women are affected two to three times more often than men.",
"   </p>",
"   <p>",
"    RA can occur in patients at any age. The peak onset is between the ages of 50 and 75, and, because of the consistently higher rates in females, the prevalence of RA in females over age 65 is up to 5 percent. In data from the Medical Expenditure Panel Survey, RA was shown to result in significant reductions in employment, productivity, and function with attendant negative impact on GNP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/5\">",
"     5",
"    </a>",
"    ]. The lifetime risk of RA in adults is 3.6 percent (1 in 28) for women and 1.7 percent (1 in 59) for men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENDER-SPECIFIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender-specific factors affect susceptibility to RA in ways that remain incompletely understood. Women are two to three times more likely to develop RA than men, perhaps due in part to the stimulatory effects of estrogen on the immune system. Estrogen inhibits T-suppressor cell function and enhances T-helper cell function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, estrogen receptors are present on synovial cells and memory T cells, and a receptor polymorphism has been associated with the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various reproductive factors may contribute to the cause of RA, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of RA is increased by nulliparity.",
"     </li>",
"     <li>",
"      Pregnancy is often associated with remission of the disease in the last trimester, but postpartum disease flares are common. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=see_link\">",
"       \"Rheumatoid arthritis and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of RA may be reduced by breastfeeding for one year or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal-fetal HLA associations may also interact to affect the manifestations of RA. In one study, women with RA were more likely to experience a remission during pregnancy if there were maternal-fetal disparities in HLA class II antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/10\">",
"     10",
"    </a>",
"    ]. Such mismatches may produce blocking antibodies to class II MHC antigens that inhibit activation of T cell clones essential for ongoing synovitis.",
"   </p>",
"   <p>",
"    Men with RA frequently have lower than normal testosterone levels. This was illustrated in a study of bioavailable testosterone in 104 male RA patients and 99 controls; hypogonadal levels of testosterone were present in a significantly greater proportion of patients (32 versus 7 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/11\">",
"     11",
"    </a>",
"    ]. Lower levels of the androgenic hormone dehydroepiandrosterone (DHEA) and higher concentrations of estradiol have also been found in men with RA, an effect that is not related to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/12\">",
"     12",
"    </a>",
"    ]. It is uncertain whether such changes in hormone levels are simply the result of chronic inflammation or whether men with abnormal testosterone and estrogenic hormone levels are at an increased risk of developing RA.",
"   </p>",
"   <p>",
"    Male sex also appears to affect disease phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with female RA patients, male patients have significantly later disease onset, are more likely to be rheumatoid factor (RF)-positive, and have higher titers of anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies. Male patients are also more likely to have histories of smoking and to possess copies of the shared epitope. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'HLA and non-HLA susceptibility genes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial data have emerged about the importance of genetic risk factors for RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Twin and sibling studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin and sibling studies implicate genetic factors in the susceptibility for RA. Monozygotic twins have a higher concordance than dizygotic twins for developing RA. In two studies of twins, the concordance for monozygotic twins was 12 to 15 percent versus 3.5 percent for dizygotic twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, the standardized incidence ratio for RA was 3 in offspring of affected parents, 4.6 in siblings, 9.3 in multiplex families, and 1.2 in spouses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, there was an increased frequency of AS, scleroderma, Sj&ouml;gren&rsquo;s syndrome, systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, PA, sarcoid, psoriasis, granulomatosis with polyangiitis (Wegener&rsquo;s), asthma, and PMR in relatives of patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other data have shown that sibship concordance rates are consistently higher when probands have severe disease, thereby suggesting that RA may develop when several genetic and environmental factors are present in the same individual. From these and similar data, it has been estimated that genetic factors contribute from 53 to 65 percent of the risk of developing RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HLA and non-HLA susceptibility genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of HLA and other genes to disease susceptibility, severity, and treatment response in RA is discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the growing list of genetic risk factors for RA, significant overlap exists with genes identified as risk factors for other autoimmune diseases, including SLE, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/18\">",
"     18",
"    </a>",
"    ]. Newly recognized genetic markers associated with RA include an allele of the Fc-gamma receptor, a polymorphism marker in the beta2-adrenergic receptor, and a low-inducible allele of the cytochrome P450 subtype 1A2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/19\">",
"     19",
"    </a>",
"    ]. Why a given genetic factor can be associated with a variable pattern of organ-system involvement in different disease states is not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3992?source=see_link\">",
"     \"Overview of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The firmest link between a genetic susceptibility factor and RA is the association of the disease with an epitope in the third hypervariable region of the HLA-DR &szlig;-chains, known as the \"shared epitope\". Individuals with the sequence leu-glu-lys-arg-ala in residues 67, 70, 71, 72, and 74 have a much higher incidence and prevalence of RA than those who do not have this epitope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/20\">",
"     20",
"    </a>",
"    ]. This sequence is found in DR4 and DR14 and some DR1 &szlig;-chains. The DR4 &szlig;-chains with the strongest associations with RA are DR&szlig;*0401, DR&szlig;*0404, DR&szlig;*0101, and DR&szlig;*1402. Although this finding has been demonstrated in many cohorts, such as those of northern European heritage, Israeli Jews, Yakima Indians, and Koreans, it does not appear to apply to all populations. Among African-Americans, for example, other genetic risk factors, many still undefined, appear to contribute significantly to disease susceptibility and severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other genetic polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsatellites and single nucleotide polymorphisms are being studied extensively in RA. For example, polymorphisms of the TNF-alpha promoter have been associated with RA, and others have been linked to better therapeutic responses to TNF inhibitors. Statistically significant associations between response to anti-TNF therapy and an RA risk allele at the PTPRC gene locus (also known as CD45) have been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased risk of RA with single nucleotide polymorphism of the protein tyrosine phosphatase N22 (PTPN22) gene that encodes a phosphatase involved in intracellular T cell signaling has been confirmed in several different populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/23\">",
"     23",
"    </a>",
"    ]. The same PTPN22 polymorphism may also increase the rate of progression of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/24\">",
"     24",
"    </a>",
"    ]. STAT4, which encodes a transcription factor that transmits signals induced by several key cytokines, has been reported to be a risk factor for both RA and systemic lupus erythematosus, suggesting a shared pathway for these to autoimmune disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional nucleotide polymorphisms related to T-cell activation and the nuclear factor &kappa;B pathway have also been linked to RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CIGARETTE SMOKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is a strong risk factor for the development of RA, particularly in individuals with the shared epitope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/27\">",
"     27",
"    </a>",
"    ]. The magnitude of the overall effect of smoking was evaluated in a retrospective report utilizing data on over 370,000 women from the Women's Health Cohort Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/28\">",
"     28",
"    </a>",
"    ]. Women who smoked at least 25 cigarettes a day for more than 20 years had a relative risk of 1.4 for developing RA compared with those who had never smoked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/28\">",
"     28",
"    </a>",
"    ]. Multivariate analysis revealed that the duration of use, but not the number of cigarettes smoked per day, was significantly associated with increased risk. A similar association with smoking and RA was noted in monozygotic and dizygotic twins discordant for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/29\">",
"     29",
"    </a>",
"    ] and in a prospective population-based study of incident RA in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increasing disease susceptibility, cigarette smoking may also be a risk factor for greater disease severity. Compared with those who had never smoked, patients with a 25 or more pack-year smoking history are more likely to be seropositive, have nodules, or have radiographically apparent erosions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nationwide case-control study from Denmark evaluated the links between genes, environment, and inflammation in a study of 515 patients with RA and 533 sex- and age-matched population controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/33\">",
"     33",
"    </a>",
"    ]. In this study, smoking among carriers of the shared epitope was estimated to account for 36 percent of all RA that was associated with anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA). The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals who were homozygous for the shared epitope had an elevated risk of ACPA-positive RA but not ACPA-negative RA. The odds ratio (OR) for ACPA-positive RA was 17.8 (95% CI 11-29).",
"     </li>",
"     <li>",
"      Strong combined gene-environment effects were observed, with markedly increased risks of ACPA-positive RA among shared epitope homozygotes who were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heavy smokers (OR 53, 95% CI 18-154)",
"     </li>",
"     <li>",
"      Heavy coffee drinkers (OR 53, 95% CI 16-183)",
"     </li>",
"     <li>",
"      Oral contraceptive users (OR 45, 95% CI 15-131)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity has been associated with development of ACPA-negative RA (OR 3.5, 95% CI 1.7-6.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the Danish study concluded that a distinction should be made between RA that is associated with ACPA and that which is not because these subtypes are likely to represent disease entities with distinct etiologies.",
"   </p>",
"   <p>",
"    Smoking cessation may help prevent the development of RA. This was suggested in a population-based study in the United States in which women who had stopped smoking more than ten years before entering the study did not share an increased risk of developing RA with their peers who were actively smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/35\">",
"     35",
"    </a>",
"    ]. In a large Swedish study, smokeless tobacco (eg, moist snuff) did not increase the risk of chronic inflammatory diseases, suggesting that inhaled components of cigarette smoke other than nicotine may be more important than nicotine itself in etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Smoking and the shared epitope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who are genetically predisposed to RA as a result of carriage of one or more alleles of the shared epitope appear to be at higher risk for developing RA if they also smoke cigarettes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'HLA and non-HLA susceptibility genes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a nationwide study in the United Kingdom of RA-discordant twins, 13 pairs of twins were also discordant for cigarette smoking. Among these twins, the smoker was the twin with RA in 12 of the 13 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genetic-environmental link was also noted in a retrospective study of 858 Swedish patients with recently diagnosed RA and 1048 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/37\">",
"     37",
"    </a>",
"    ]. There was a marked increase in risk associated with cigarette smoking. Compared with those who never smoked, the relative risk in current smokers with one or two shared epitopes was 2.3- and 5.6-fold higher, respectively. The relative risk was even higher (5.5 and 15.7) in patients who were rheumatoid factor (RF)-positive.",
"   </p>",
"   <p>",
"    The increase in risk associated with smoking in individuals with the shared epitope may be affected primarily by citrullination of proteins in inflamed tissues. This was suggested in a study in which the association between smoking and RA was strongest (relative risk 21) among individuals with antibodies to citrullinated proteins as detected by the anti-cyclic citrullinated peptide (anti-CCP) assay for ACPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, there was no evidence of an interaction between smoking and the shared epitope in patients who were ACPA-negative, including a subset who were ACPA-negative but RF positive (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of rheumatoid arthritis\", section on 'Citrullinated proteins and peptides'",
"    </a>",
"    ), nor was an association noted between cigarette smoking, ACPA status, or carriage of shared epitope in a study of 300 African American patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study evaluated the genetic-environment-immune link in 515 Danish RA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/40\">",
"     40",
"    </a>",
"    ]. Of these, 309 had ACPA; of 456 tested, 262 had the shared epitope. The odds ratio (for RA) for those having both the shared epitope and having ACPA was 17.8. For the ACPA-positive, shared epitope positive RA patients, the odds ratio for those who smoked was 52.6 to 57.4 (versus 17.4 in nonsmokers). For those who consumed alcohol the odds ratio was 10.5 to 27 (for non-drinkers the odds-ratio was 50.1). The odds ratio for those who drank coffee was 27.4 to 53.3 (versus 13.0 for non-coffee drinkers). The odds ratio for women who used oral contraceptives was 44.6 (versus 32.3 for non-users). Furthermore, the odds ratio for ACPA-positive, shared epitope homozygous patients who were unmarried was 177 and was 243 for those without a job. The authors concluded that smoking among carriers of the shared epitope (either heterozygotes or homozygotes) accounted for 36 percent of all ACPA-positive RA patients.",
"   </p>",
"   <p>",
"    As mentioned above, some have interpreted these data to indicate that the shared epitope is a marker for ACPA rather than an independent risk factor for RA per se. Peptidyl arginase deiminase (PADI) is the enzyme that modifies arginine residues to citrulline. One haplotype in the PADI 4 gene leads to increased levels of the enzyme and susceptibility to RA in some Asian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/41\">",
"     41",
"    </a>",
"    ]. In a study from Korea of 341 RA patients, PADI 4 haplotypes were associated with &ldquo;seropositive&rdquo; (eg, ACPA positive) RA of short disease duration, while the shared epitope was associated with longstanding, seropositive RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the shared epitope, there may be other genetic components that predispose to the development of more severe disease in smokers. Among a group of 96 mostly Caucasian women with RA, 30 were homozygous for a nonfunctional allele at the M1 locus for the enzyme glutathione S-transferase (GSTM1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/43\">",
"     43",
"    </a>",
"    ]. Among these women, those who smoked had significantly more severe joint damage than those who had never smoked (Larsen score 113 versus 83, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/43\">",
"     43",
"    </a>",
"    ]. The relation between smoking and disease severity was not seen in the 66 women with at least one functional GSTM1 allele. Antibodies to the CEP-1 peptide from citrullinated alpha-enolase show an association with HLA-DRB1*0401, *0404, PTPN22, and smoking cigarettes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSSIBLE ROLE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above hormonal, genetic, and environmental risk factors, although important in determining susceptibility to RA, are neither necessary nor sufficient to cause the disease. Additional factors must be present to trigger disease onset.",
"   </p>",
"   <p>",
"    Infection has been suspected to be an inciting factor in RA. Among the bacteria that have been suspected are Proteus mirabilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/45\">",
"     45",
"    </a>",
"    ], Mycoplasma species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/46-48\">",
"     46-48",
"    </a>",
"    ], and Porphyromonas gingivalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/44,49\">",
"     44,49",
"    </a>",
"    ]. However, despite intensive study of these and other organisms, there is as yet no proof of bacterial infection as a contributor to RA. Viral pathogens remain an active area of investigation.",
"   </p>",
"   <p>",
"    Several cellular mechanisms have been identified that could facilitate activation of inflammation by infectious agents. Two examples are toll-like receptors and the inflammasome complex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toll-like receptors (TLRs) recognize preserved structures in bacteria and, when activated by inflammatory mediators such as cytokines or chemokines, can stimulate antigen-presenting cells, enhance adaptive immune responses, and trigger inflammatory mediator release. Many of these TLRs, especially 3 and 4, are expressed by rheumatoid synovial tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. In addition, bacterial peptidoglycans in RA synovial tissue have the potential to activate TLRs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=see_link\">",
"       \"Toll-like receptors: Roles in disease and therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The inflammasome complex is critical to the recognition of infectious pathogens. One component of this complex is cryopyrin, a protein that is abundant in rheumatoid synovium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H4#H4\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Pathogenesis of disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15586249\">",
"    <span class=\"h2\">",
"     Porphyromonas gingivalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease has been associated with RA in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]; a relationship with disease severity has also been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/54,59\">",
"     54,59",
"    </a>",
"    ]. The major etiologic agent associated with the pathogenesis of periodontitis is Porphyromonas gingivalis. P. gingivalis contains the enzyme peptidyl arginine deiminase, which allows the bacteria to generate citrullinated peptides in vivo, leading to the hypothesis that, in a genetically susceptible individual (carrying the shared epitope), the presence of such peptides may contribute to breaking tolerance to endogenous citrullinated antigens, potentially resulting in production of anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA) and contributing to the development of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/44,49,55\">",
"     44,49,55",
"    </a>",
"    ]. Additionally, P. gingivalis expresses other proteinases that may also play a role in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of RA patients and their unaffected relatives, from among a genetically predisposed population, has documented that anti-P. gingivalis antibodies were associated with ACPA but not with RF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, in addition to cigarette smoking, another environmental factor, the infectious agent P. gingivalis, is associated with ACPA and RA in the presence of the shared epitope. Additional studies are needed to clarify the relationships among these different factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating viruses as possible etiologic factors among patients with RA have been more profitable than similar studies for bacteria. Isolates of Rubella antigen and adenoviral nucleotide sequences, for example, have been obtained from synovial specimens. In addition, lymphocytes from several patients are readily activated by cytomegalovirus antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epstein-Barr virus and retroviruses have been best studied. There are conflicting data on the role of human parvovirus B19 in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Epstein Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant effort has been devoted to evaluating a possible association between Epstein Barr virus (EBV) and RA. This work was prompted in part by the finding in 1975 and in later studies of an antibody in the sera of rheumatoid patients that reacted with an Epstein Barr nuclear antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional support for a relationship includes the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EBV is a polyclonal activator of B lymphocytes, including those that express rheumatoid factor.",
"     </li>",
"     <li>",
"      Patients with RA have an increased humoral and cellular immune response to EBV, Brucella ovis, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      lactis antigens that contain the QKRAA sequence, which is the same sequence found in the shared epitope [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are conflicting data whether B cells in the synovium of patients with RA are or are not more likely to harbor EBV RNA, particularly among those with HLA-DR4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with RA may have an increased EBV viral load. This was suggested in a report in which 84 patients with RA were compared with 69 healthy controls and 22 patients with other rheumatic diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/69\">",
"       69",
"      </a>",
"      ]. The EBV DNA load was increased nearly 10-fold in patients with RA, remained stable over time, and was not influenced by treatment with disease modifying anti-rheumatic drugs (DMARDs).",
"     </li>",
"     <li>",
"      Polymorphous lymphoproliferative disorder, containing large lymphoid cells together with small lymphocytes, plasma cells, macrophages,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eosinophils, develops in some patients with autoimmune diseases and is often EBV-associated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Retroviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing enthusiasm for the role of retroviruses as both a cause and amplifier of RA, since these viruses provide all of the required mechanisms to generate a chronic inflammatory and proliferative synovitis. A retrovirus can activate synovial monocytes and lining cells to induce cytokines and metalloproteases, which then bypass lymphocytes as a major causative component of the inflammatory response. By activating both T cells and synovial cells and perhaps by contributing superantigen from its own proteins, a retrovirus could promote the development of RA.",
"   </p>",
"   <p>",
"    Human T-lymphotropic virus type I (HTLV-I), the etiologic agent of adult T cell leukemia-lymphoma, has often been associated with an inflammatory arthropathy in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, women with RA in Japan have a fivefold higher seroprevalence of HTLV-I than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/72\">",
"     72",
"    </a>",
"    ]. However, none of the data suggests that this virus is causative. It is more likely that HTLV-I is another mild predisposing factor. Contrary to some earlier reports, investigators using a real-time polymerase chain reaction assay were unable to detect human retrovirus-5 proviral DNA in synovial tissue and blood from rheumatoid patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUPERANTIGENS AND HEAT SHOCK PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superantigens can activate multiple clones of T cells (1 in 10 cells) through a largely MHC-independent process. By comparison, a specific antigen presented in context of the HLA class II cell surface antigens can activate only 1 in 10,000 T cells.",
"   </p>",
"   <p>",
"    Examples of superantigens are the staphylococcal endotoxins and heat shock proteins (HSPs). HSPs are intracellular proteins induced by environmental insults, including heat, infectious agents, and oxidative injury, and are remarkably conserved across species.",
"   </p>",
"   <p>",
"    The first possible link between HSPs, infection, and RA was the finding that the component of Mycobacterium tuberculosis used with Freund's adjuvant to produce \"adjuvant arthritis\" in rats was a 65 kD HSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two indirect findings supporting an association between HSPs and RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 65 kD protein activates lymphocytes from patients with RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies against a human HSP were produced by B lymphocytes from rheumatoid synovial tissue that was transformed by EBV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most logical hypothesis implicating HSPs as causative in RA is that these proteins share antigenic determinants with other host proteins, thereby resulting in the development of cross-reacting antibodies that could induce an autoimmune response (ie, molecular mimicry). As an example, two proteins that possess the shared epitope (QKRAA) on DR&szlig;1*0401 are EBV gp110 and Escherichia coli dnaJ. The latter molecule is a heat shock protein and strongly antigenic. Specific antibodies against dnaJ cross-react with DR&szlig;1*0401 (Dw4)-positive cells, but not with cells that express other alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By cross-reactivity, some individuals with HLA-DR4 in whom T cells are skewed towards the epitope QKRAA because of positive selection may develop a systemic autoimmune response by producing high affinity antibodies against QKRAA; these autoantibodies could in turn lead to a self-perpetuating synovitis. Other patients who express HLA-DR4 might not have a peripheral T cell population skewed toward QKRAA and would, therefore, not mount an immune response sufficient to generate a synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, heat shock proteins have also been demonstrated to have disease suppressive activities. HSPs, added to cultures of human peripheral blood mononuclear cells, significantly inhibited secretion of IL-6 and TNF-alpha by these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the discovery of RF in 1940, much research has linked this autoantibody to the pathophysiology of severe RA. Although it is clear that the presence of RF alone does not cause RA, there is no doubt that patients with significant RF titers have a greater likelihood of extraarticular disease than do seronegative patients. Classic experiments by Hollander and colleagues showed RF injected into the joint of a patient with RA led to a marked inflammatory response, in contrast to the injection of IgG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RF and anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA) may be present in the blood prior to the appearance of arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/81-86\">",
"     81-86",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of healthy individuals from Finland, 9 of 129 subjects with positive RF subsequently developed seropositive RA over a 10 year investigation period, compared with only 12 of 7000 subjects with negative tests (7 versus 0.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 83 patients with RA who had stored blood samples available as a result of blood donation or prenatal testing, the prevalence of ACPA was significantly higher in patients preceding diagnosis than in controls (34 versus 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/82\">",
"       82",
"      </a>",
"      ]. There was also a significant increase in the prevalence of RFs of all isotypes (17, 19, and 33 percent for RF of IgG, IgM, and IgA isotype, respectively).",
"     </li>",
"     <li>",
"      In a case-control study of 79 patients with RA who had stored serum available from blood donations prior to the development of RA (1 to 51 samples per patient, dating up to 15 years prior onset of RA), 49 percent had detectable ACPA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-IgM RF on at least one occasion and 41 percent had ACPA detectable when symptoms first developed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a nested case-control study of 69 patients diagnosed with RA for whom stored pre-diagnosis blood samples were available, marked elevations in several cytokines, cytokine receptors, and chemokines were present before disease onset compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/86\">",
"       86",
"      </a>",
"      ]. Notably, levels were particularly increased in individuals also positive for anti-CCP and RF, and, after disease onset, immune system activation was more generalized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these autoantibodies may represent clinically silent disease, the development of such autoantibodies can also be viewed as a risk factor for the later development of disease. The sensitivity of a positive ACPA",
"    <strong>",
"     and",
"    </strong>",
"    a positive RF in the 1.5 years prior to diagnosis has ranged from 18 to 30 percent and the specificity from 99 to 100 percent.",
"   </p>",
"   <p>",
"    The combination of ACPA with the genetic markers, the shared epitope, and PTPN22 greatly increases the risk for the development of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OCCUPATIONAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational exposure to dust and fibers may increase the risk of developing RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Silica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silica exposure increased the risk for the development of RA in Swedish men, independent of cigarette smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/88\">",
"     88",
"    </a>",
"    ]. These results are consistent with the conclusions of an earlier meta-analysis of 10 studies that concluded there was a significant association between occupational exposure and RA (relative risk 3.43, 95% CI 2.25-5.22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other occupational exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other occupations associated with an increased risk of developing RA include electrical work, wood work, and those that involve asbestos exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol intake may reduce the risk of developing RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/27,90\">",
"     27,90",
"    </a>",
"    ]. In a prospective study of a population-based cohort of over 34,000 women in Sweden, the moderate use of alcohol (drinking at least four glasses of alcohol weekly) resulted in a greater than one-third reduction in the risk of developing RA, compared with never drinking alcohol (relative risk 0.63, 95% CI 0.42-0.96).",
"   </p>",
"   <p>",
"    Increased birthweight is associated with increased risk for RA, while duration of breastfeeding and socioeconomic status are inversely associated with RA risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/27\">",
"     27",
"    </a>",
"    ]. Obesity may also play a role in development of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/34\">",
"     34",
"    </a>",
"    ]. High consumption of red meat does not increase the risk for developing RA, and the roles of vitamin D and oral contraceptives remain equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39593/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual incidence of rheumatoid arthritis (RA) is approximately 40 per 100,000, and the prevalence is about 1 percent in Caucasians but differs in other populations. Women are affected two to three times more often than men. RA can occur in patients at any age, and the peak onset is between the ages of 50 and 75. The lifetime risk of RA in adults is 3.6 percent (1 in 28) for women and 1.7 percent (1 in 59) for men. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gender-specific factors affect susceptibility to RA in ways that remain incompletely understood. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Gender-specific factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substantial data have emerged about the importance of genetic risk factors for RA from studies of twins and siblings, HLA and non-HLA susceptibility genes, and other polymorphisms. The firmest link between a genetic susceptibility factor and RA is the association of the disease with an epitope in the third hypervariable region of the HLA-DR &szlig;-chains, known as the \"shared epitope.\" (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cigarette smoking is a strong risk factor for the development of RA, particularly in individuals with the shared epitope. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cigarette smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A role for viral or bacterial infection as an inciting trigger for RA has been hypothesized, but no single agent has been proven responsible. Some studies implicate a role for toll-like receptors, the inflammasome, and responses to superantigens in linking infection and the autoimmune arthritis process. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Possible role of infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Superantigens and heat shock proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant RF titers have a greater likelihood of extraarticular disease than do seronegative patients, although rheumatoid factor (RF) alone does not cause RA. RF and anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibodies (ACPA) may be present in the blood prior to the appearance of arthritis, and the combination of ACPA with the genetic markers, the shared epitope, and PTPN22 greatly increases the risk for the development of RA. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various occupational and other exposures as well as environmental factors have been associated with modifying the risk for the development of RA. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Occupational exposures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Other risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/1\">",
"      Rothschild BM, Turner KR, DeLuca MA. Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 1988; 241:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/2\">",
"      Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/3\">",
"      Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/4\">",
"      Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/5\">",
"      Sullivan PW, Ghushchyan V, Huang XY, Globe DR. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010; 37:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/6\">",
"      Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/7\">",
"      Ansar Ahmed S, Dauphinee MJ, Talal N. Effects of short-term administration of sex hormones on normal and autoimmune mice. J Immunol 1985; 134:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/8\">",
"      Takagi H, Ishiguro N, Iwata H, Kanamono T. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol 2000; 27:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/9\">",
"      Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum 2004; 50:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/10\">",
"      Nelson JL, Hughes KA, Smith AG, et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993; 329:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/11\">",
"      Tengstrand B, Carlstr&ouml;m K, Hafstr&ouml;m I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 2002; 41:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/12\">",
"      Tengstrand B, Carlstr&ouml;m K, Fell&auml;nder-Tsai L, Hafstr&ouml;m I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. J Rheumatol 2003; 30:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/13\">",
"      Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum 2006; 54:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/14\">",
"      Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986; 13:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/15\">",
"      Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993; 32:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/16\">",
"      Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 2009; 60:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/17\">",
"      MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/18\">",
"      Jawaheer D, Seldin MF, Amos CI, et al. A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001; 68:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/19\">",
"      Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 2010; 22:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/20\">",
"      de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum 2002; 46:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/21\">",
"      Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/22\">",
"      Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/23\">",
"      Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/24\">",
"      Lie BA, Viken MK, Odeg&aring;rd S, et al. Associations between the PTPN22 1858C-&gt;T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2007; 66:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/25\">",
"      Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/26\">",
"      McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/27\">",
"      Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol 2009; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/28\">",
"      Karlson EW, Lee IM, Cook NR, et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999; 42:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/29\">",
"      Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/30\">",
"      Criswell LA, Saag KG, Mikuls TR, et al. Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. Ann Rheum Dis 2006; 65:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/31\">",
"      Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/32\">",
"      Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/33\">",
"      Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007; 56:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/34\">",
"      Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8:R133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/35\">",
"      Criswell LA, Merlino LA, Cerhan JR, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med 2002; 112:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/36\">",
"      Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med 2010; 181:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/37\">",
"      Padyukov L, Silva C, Stolt P, et al. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/38\">",
"      Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/39\">",
"      Mikuls TR, Hughes LB, Westfall AO, et al. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/40\">",
"      Khuder SA, Peshimam AZ, Agraharam S. Environmental risk factors for rheumatoid arthritis. Rev Environ Health 2002; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/41\">",
"      Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/42\">",
"      Cha S, Choi CB, Han TU, et al. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum 2007; 56:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/43\">",
"      Mattey DL, Hutchinson D, Dawes PT, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum 2002; 46:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/44\">",
"      Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/45\">",
"      Deighton CM, Gray J, Bint AJ, Walker DJ. Specificity of the proteus antibody response in rheumatoid arthritis. Ann Rheum Dis 1992; 51:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/46\">",
"      Schaeverbeke T, Renaudin H, Clerc M, et al. Systematic detection of mycoplasmas by culture and polymerase chain reaction (PCR) procedures in 209 synovial fluid samples. Br J Rheumatol 1997; 36:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/47\">",
"      Horowitz S, Evinson B, Borer A, Horowitz J. Mycoplasma fermentans in rheumatoid arthritis and other inflammatory arthritides. J Rheumatol 2000; 27:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/48\">",
"      Hoffman RW, O'Sullivan FX, Schafermeyer KR, et al. Mycoplasma infection and rheumatoid arthritis: analysis of their relationship using immunoblotting and an ultrasensitive polymerase chain reaction detection method. Arthritis Rheum 1997; 40:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/49\">",
"      Mikuls TR. Help stop tooth decay...and prevent RA? J Rheumatol 2010; 37:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/50\">",
"      Brentano F, Kyburz D, Schorr O, et al. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 2005; 233:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/51\">",
"      Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008; 58:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/52\">",
"      Schrijver IA, Melief MJ, Tak PP, et al. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis Rheum 2000; 43:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/53\">",
"      Rosengren S, Hoffman HM, Bugbee W, Boyle DL. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2005; 64:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/54\">",
"      Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001; 72:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/55\">",
"      Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/56\">",
"      Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/57\">",
"      Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: a review. J Periodontol 2005; 76:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/58\">",
"      de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 2008; 35:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/59\">",
"      Mikuls TR, Payne JB, Reinhardt RA, et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009; 9:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/60\">",
"      Hitchon CA, Chandad F, Ferucci ED, et al. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 2010; 37:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/61\">",
"      Ford DK, da Roza DM, Schulzer M, et al. Persistent synovial lymphocyte responses to cytomegalovirus antigen in some patients with rheumatoid arthritis. Arthritis Rheum 1987; 30:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/62\">",
"      Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:8227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/63\">",
"      Peterlana D, Puccetti A, Beri R, et al. The presence of parvovirus B19 VP and NS1 genes in the synovium is not correlated with rheumatoid arthritis. J Rheumatol 2003; 30:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/64\">",
"      Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sj&ouml;gren's syndrome. J Clin Invest 1975; 55:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/65\">",
"      Ferrell PB, Aitcheson CT, Pearson GR, Tan EM. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest 1981; 67:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/66\">",
"      La Cava A, Nelson JL, Ollier WE, et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest 1997; 100:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/67\">",
"      Saal JG, Krimmel M, Steidle M, et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum 1999; 42:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/68\">",
"      Niedobitek G, Lisner R, Swoboda B, et al. Lack of evidence for an involvement of Epstein-Barr virus infection of synovial membranes in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2000; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/69\">",
"      Balandraud N, Meynard JB, Auger I, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003; 48:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/70\">",
"      Nakamichi N, Wada N, Kohara M, et al. Polymorphous lymphoproliferative disorder: a clinicopathological analysis. Virchows Arch 2010; 456:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/71\">",
"      Sato K, Maruyama I, Maruyama Y, et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 1991; 34:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/72\">",
"      Eguchi K, Origuchi T, Takashima H, et al. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/73\">",
"      Piper KE, Hanssen AD, Lewallen DG, et al. Lack of detection of human retrovirus-5 proviral DNA in synovial tissue and blood specimens from individuals with rheumatoid arthritis or osteoarthritis. Arthritis Rheum 2006; 55:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/74\">",
"      van Eden W, Thole JE, van der Zee R, et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988; 331:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/75\">",
"      Bahr GM, Rook GA, al-Saffar M, et al. Antibody levels to mycobacteria in relation to HLA type: evidence for non-HLA-linked high levels of antibody to the 65 kD heat shock protein of M. bovis in rheumatoid arthritis. Clin Exp Immunol 1988; 74:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/76\">",
"      Burmester GR, Altstidl U, Kalden JR, Emmrich F. Stimulatory response towards the 65 kDa heat shock protein and other mycobacterial antigens in patients with rheumatoid arthritis. J Rheumatol 1991; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/77\">",
"      Albani S, Keystone EC, Nelson JL, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995; 1:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/78\">",
"      Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996; 17:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/79\">",
"      Tukaj S, Kotlarz A, Jozwik A, et al. Hsp40 proteins modulate humoral and cellular immune response in rheumatoid arthritis patients. Cell Stress Chaperones 2010; 15:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/80\">",
"      Rawson AJ, Hollander JL, Quismorio FP, Abelson NM. Experimental arthritis in man and rabbit dependent upon serum anti-immunoglobulin factors. Ann N Y Acad Sci 1969; 168:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/81\">",
"      Aho K, Heli&ouml;vaara M, Maatela J, et al. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991; 18:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/82\">",
"      Rantap&auml;&auml;-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/83\">",
"      Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/84\">",
"      Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6:R303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/85\">",
"      Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012; 345:e5244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/86\">",
"      Kokkonen H, S&ouml;derstr&ouml;m I, Rockl&ouml;v J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/87\">",
"      Rantap&auml;&auml;-Dahlqvist S. What happens before the onset of rheumatoid arthritis? Curr Opin Rheumatol 2009; 21:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/88\">",
"      Stolt P, K&auml;llberg H, Lundberg I, et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2005; 64:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/89\">",
"      Cooper GS. Occupational exposures and risk of rheumatoid arthritis: continued advances and opportunities for research. J Rheumatol 2008; 35:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39593/abstract/90\">",
"      Di Giuseppe D, Alfredsson L, Bottai M, et al. Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study. BMJ 2012; 345:e4230.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7519 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39593=[""].join("\n");
var outline_f38_42_39593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENDER-SPECIFIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Twin and sibling studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HLA and non-HLA susceptibility genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other genetic polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CIGARETTE SMOKING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Smoking and the shared epitope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSSIBLE ROLE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15586249\">",
"      Porphyromonas gingivalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Epstein Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Retroviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUPERANTIGENS AND HEAT SHOCK PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OCCUPATIONAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Silica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other occupational exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3992?source=related_link\">",
"      Overview of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=related_link\">",
"      Rheumatoid arthritis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_42_39594="Cytogenetics in acute myeloid leukemia";
var content_f38_42_39594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytogenetics in acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Yanming Zhang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Michelle M Le Beau, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/42/39594/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/42/39594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic analysis of metaphase cells is a key component to the evaluation of all patients with newly diagnosed or suspected acute myeloid leukemia (AML). The malignant cells in most patients with AML have non-random, acquired clonal chromosomal abnormalities. In some cases, specific cytogenetic abnormalities are closely, and sometimes uniquely, associated with morphologically and clinically distinct subsets of the disease. As such, the 2008 WHO classification of tumors of the hematopoietic and lymphoid tissues uses genetic findings in addition to morphologic, immunophenotypic, and clinical features to define distinct subtypes of AML. In addition to establishing the type of AML, specific cytogenetic abnormalities have diagnostic, prognostic, and therapeutic importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Molecular genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=see_link&amp;anchor=H6273191#H6273191\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review selected cytogenetic abnormalities in both de novo and therapy-related acute myeloid leukemia (t-AML). An overview of cytogenetics in hematologic malignancies, including definitions, methods of detection, the genetic consequences of chromosomal translocation, and the relationship between these chromosomal abnormalities and the pathobiology of AML are discussed separately. A risk stratification of AML based upon molecular genetics is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link\">",
"     \"Molecular genetics of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following terminology will be used in this review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal translocation (t) is the process by which a break in at least two different chromosomes occurs, with exchange of genetic material. Reciprocal translocation refers to an exchange between two or more chromosomes in which there is no obvious overall loss of chromosomal material. An example of a reciprocal translocation is the Philadelphia chromosome, t(9;22)(q34;q11.2), seen in chronic myeloid leukemia.",
"     </li>",
"     <li>",
"      Chromosomal deletion (del) means loss of chromosomal material. An interstitial deletion results from two breaks in a single chromosome with the loss of intervening material. An example of an interstitial deletion is the 5q- syndrome, or myelodysplastic syndrome with an isolated del(5q), in which a variable portion (often the segment between bands q14 and q33) of the long arm of chromosome 5 is lost.",
"     </li>",
"     <li>",
"      Monosomy is a form of genetic loss in which an entire chromosome is lost (eg, monosomy 7 or -7).",
"     </li>",
"     <li>",
"      Chromosomal inversion (inv) requires two breaks in the same chromosome with rotation of the intervening material. An example is inv(16)(p13.1q22), wherein genes previously on opposite ends of chromosome 16 are juxtaposed after the rearrangement.",
"     </li>",
"     <li>",
"      Chromosomal bands are alternating light and dark segments that result from various staining procedures. The banding pattern of each chromosome is unique.",
"     </li>",
"     <li>",
"      Rearranged chromosomes are identified in part by which chromosome has retained its centromere, ie, the derivative (der) chromosome.",
"     </li>",
"     <li>",
"      A \"monosomal karyotype\" is defined as at least two autosomal monosomies or a single autosomal monosomy in the presence of one or more structural cytogenetic abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the case of the Philadelphia chromosome in chronic myeloid leukemia, for example, the most common translocation is between the long arm of chromosome 9 at band q34 (9q34) and the long arm of chromosome 22 at band q11.2 (22q11.2). Standard nomenclature is to include the translocation in one set of parentheses and the breakpoints in a second set of parentheses. Thus, this specific translocation would be denoted as t(9;22)(q34;q11.2). As a result of this translocation, the ABL1 gene at band 9q34 is juxtaposed with the BCR gene at band 22q11.2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE MYELOID LEUKEMIA DE NOVO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification of the acute leukemias has traditionally relied upon morphology, reflecting the predominant cell type and relating that cell to its presumed normal counterpart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/5\">",
"     5",
"    </a>",
"    ]. The correlation of cytogenetic abnormalities with the morphological features of acute leukemia was largely made possible by development of the French-American-British (FAB) classification system of the acute leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. AML is now classified using the 2008 WHO classification system, which is based upon a combination of morphology, immunophenotype, genetics, and clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using standard banding techniques, 50 to 60 percent of patients with AML de novo have abnormal karyotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a study of 5876 young adults with newly diagnosed de novo or secondary AML, 31 percent of patients had a single abnormality on karyotype analysis, whereas 2, 3, 4, and 5 or more abnormalities were seen in 13, 5, 2, and 7 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common karyotype results seen in this study were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal (41 percent)",
"     </li>",
"     <li>",
"      t(15;17)(q24.1;q21.1) and variants (13 percent)",
"     </li>",
"     <li>",
"      Trisomy 8 (10 percent)",
"     </li>",
"     <li>",
"      t(8;21)(q22;q22) and variants (7 percent)",
"     </li>",
"     <li>",
"      11q rearrangements (6 percent)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       inv(16)(p13.1q22)/t(16;16)(p13.1;q22)",
"      </span>",
"      (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of cytogenetic abnormalities increases markedly when techniques for culturing leukemia cells and for obtaining prophase and prometaphase chromosomes are used. Some laboratories have reported clonal abnormalities in up to 85 percent of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993128343\">",
"    <span class=\"h2\">",
"     Using cytogenetic analysis to diagnose and classify AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML is diagnosed by bone marrow aspiration and biopsy using morphologic, cytochemical, immunophenotypic, and",
"    <span class=\"nowrap\">",
"     cytogenetic/molecular",
"    </span>",
"    analysis. Cases are then classified into appropriate subtypes, according to the current WHO classification scheme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. The subtype is important to help select appropriate therapy in some instances, to provide prognostic information, and in the future to help clarify underlying molecular pathogenesis so that improved therapies might be developed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Bone marrow infiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most cases of AML, myeloid blast forms must account for at least 20 percent of the total cellularity of the bone marrow biopsy sample. Exceptions to this include leukemias with certain genetic abnormalities or myeloid sarcoma, which are considered diagnostic of AML without regard to the blast count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following cytogenetic abnormalities, if found, result in the diagnosis of AML regardless of blast count:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (previously AML1-ETO) &mdash; (See",
"      <a class=\"local\" href=\"#H7\">",
"       '8;21 translocation in AML'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 &mdash; (See",
"      <a class=\"local\" href=\"#H993131070\">",
"       'Inv(16) and t(16;16)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      APL with t(15;17)(q24.1;q21.1); PML-RARA &mdash; (See",
"      <a class=\"local\" href=\"#H8\">",
"       '15;17 translocation in APL'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following four AML subtypes, which require at least 20 percent myeloid blasts for diagnosis, have been identified as subcategories of AML with genetic abnormalities of prognostic significance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AML with t(9;11)(p22;q23); MLLT3-MLL &mdash; (See",
"      <a class=\"local\" href=\"#H993131111\">",
"       'Rearrangements of 11q23'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      AML with t(6;9)(p23;q34); DEK-NUP214 &mdash; (See",
"      <a class=\"local\" href=\"#H983671238\">",
"       't(6;9)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1- MECOM (MDS1-EVI1) &mdash; (See",
"      <a class=\"local\" href=\"#H11\">",
"       't(3;3) and inv(3) in AML with thrombocytosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 &mdash; (See",
"      <a class=\"local\" href=\"#H983671253\">",
"       't(1;22)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These seven subtypes of AML are collectively identified in the 2008 WHO classification system as AML with recurrent genetic abnormalities. Each of these balanced translocations or inversions results in a fusion gene encoding a chimeric protein that participates in leukemogenesis, but is not necessarily sufficient for the development of AML by itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993127944\">",
"    <span class=\"h2\">",
"     Using the cytogenetic pattern for AML prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its use in classification, cytogenetics correlates with prognosis. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific structural rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, a number of specific chromosomal translocations and inversions occur in AML, often in particular association with an AML subtype with distinctive morphology and treatment response. The following sections describe cytogenetic abnormalities that are of particular diagnostic or prognostic importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     8;21 translocation in AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;The balanced translocation t(8;21)(q22;q22), RUNX1-RUNX1T1 (previously AML1-ETO), is seen in approximately 7 percent of adults with newly diagnosed AML (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]; it is also the most frequent abnormality in children with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;It is one of the three cytogenetic abnormalities in AML which, if found, result in the diagnosis of AML regardless of the bone marrow blast count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using prior classification schemes, t(8;21) was seen in approximately 40 percent of those diagnosed with acute myeloblastic leukemia with maturation (AML-M2) and an abnormal karyotype (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This translocation was initially thought to be restricted to patients with AML-M2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/5\">",
"     5",
"    </a>",
"    ]. However, 7 percent of 44 patients analyzed at the Fourth International Workshop who had a t(8;21) and adequate bone marrow material available for morphological review had a diagnosis of acute myelomonocytic leukemia (AMMoL or AML-M4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This translocation juxtaposes the RUNX1 (previously AML1 or core binding factor alpha-2) gene on chromosome 21 with the RUNX1T1 (previously ETO or MTG8) gene on chromosome 8 to form a",
"    <span class=\"nowrap\">",
"     RUNX1/RUNX1T1",
"    </span>",
"    chimeric product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. The RUNX1 protein is a member of a family of transcription factors with homology to the pair-rule Drosophila gene, Runt. RUNX1 heterodimerizes with another protein, core binding factor beta (CBFB, also known as PEBP2 beta), to form a transcription factor. The CBFB gene is located at 16q22, which is the breakpoint in the inv(16) and t(16;16) rearrangements. (See",
"    <a class=\"local\" href=\"#H993131070\">",
"     'Inv(16) and t(16;16)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB",
"    </span>",
"    transcription factor binds directly to an enhancer core motif that is present in the transcriptional regulatory regions of a number of genes that are critical to hematopoietic stem and progenitor cell growth, differentiation, and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/15\">",
"     15",
"    </a>",
"    ]. These genes are part of the",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    signaling which contribute to increased survival of tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Mutant mice with loss of RUNX1 or CBFB gene function are deficient in hematopoiesis, and die during embryogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A similar result has been noted in gene targeting studies in which the",
"    <span class=\"nowrap\">",
"     RUNX1/RUNX1T1",
"    </span>",
"    allele was \"knocked in\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/21\">",
"     21",
"    </a>",
"    ]. The findings indicated that the",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB-regulated",
"    </span>",
"    target genes are essential for hematopoiesis of all lineages. Among the genes regulated by",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB",
"    </span>",
"    are those encoding interleukin (IL)-3, GM-CSF, the CSF1 receptor, myeloperoxidase, and neutrophil elastase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RUNX1-RUNX1T1 can interact with the enhancer core motif, since the DNA-binding domain is retained, but it interferes with normal activation of gene expression by the normal",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB",
"    </span>",
"    transcription factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. In addition, RUNX1-RUNX1T1 has other functions, directly generating dysplastic hematopoietic progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/21\">",
"     21",
"    </a>",
"    ] and possibly activating expression of other genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, leukemogenesis by RUNX1-RUNX1T1 probably results from both altered transcriptional regulation of normal RUNX1 target genes and activation of new target genes that prevent programmed cell death",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular differentiation pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Two-hit hypothesis of leukemogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The t(8;21) identifies a morphologically and clinically distinct subset with the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The myeloblasts tend to have indented nuclei.",
"     </li>",
"     <li>",
"      The cytoplasm is generally basophilic with a prominent paranuclear hof that may contain a few azurophilic granules.",
"     </li>",
"     <li>",
"      Promyelocytes, myelocytes, and metamyelocytes are often prominent and may be large; their cytoplasm has a waxy, orange appearance and lacks a granular texture in Romanowski-stained specimens.",
"     </li>",
"     <li>",
"      Auer rods are easily identified, and several may be present in a single cell.",
"     </li>",
"     <li>",
"      Bone marrow eosinophilia is common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The malignant cells in some of these patients appear cytogenetically normal or contain only a detectable -Y or del(9q) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/25\">",
"     25",
"    </a>",
"    ]. However, fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) methods will demonstrate the cryptic RUNX1-RUNX1T1 rearrangement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AML with the t(8;21) has a favorable prognosis in adults, but children have had a poor outcome. The median age in adults is approximately 25 to 30 years, significantly younger than that for the total group of adults with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9,26,27\">",
"     9,26,27",
"    </a>",
"    ]. The identification of t(8;21) results in the diagnosis of AML, regardless of blast count. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The complete remission rate is uniformly high and, with intensive postremission consolidation chemotherapy, the expected disease-free survival exceeds two years, after which time relapses are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ]. In one study of 5876 younger adults with newly diagnosed AML, the 421 patients with t(8;21) demonstrated a 97 percent rate of complete response and 10-year overall survival of 61 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. Corresponding rates for patients with a normal karyotype were 90 and 38 percent, respectively.",
"   </p>",
"   <p>",
"    Interestingly, some patients who have remained in continuous remission for as long as eight years have still had RUNX1-RUNX1T1 mRNA detectable by PCR techniques in circulating leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The longer-term outcome of such patients is not known, but persistence of this particular rearrangement may not by itself predict a progressive and malignant phenotype. Serial quantitative measurements in such patients may be helpful as increasing values for minimal residual disease over time may be associated with a higher risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Nevertheless, therapeutic decisions cannot at present be based solely upon a positive signal with RT-PCR. In comparison, patients who are RT-PCR negative are probably cured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     15;17 translocation in APL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute promyelocytic leukemia (APL, previously called AML-M3) is characterized by the balanced translocation t(15;17)(q24.1;q21.1) (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This rearrangement is seen in 13 percent of newly diagnosed AML and is highly specific for APL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. This translocation has not been found in patients with any other type of leukemia or with a solid tumor, although there are rare cases of t(15;17) occurring in chronic myeloid leukemia (CML), coincident with development of a promyelocytic blast crisis. It is one of the three cytogenetic abnormalities in AML which, if found, result in the diagnosis of AML regardless of blast count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The breakpoint on chromosome 17 occurs within the first intron of the alpha retinoic acid receptor gene (RARA) in most patients, whereas the break on chromosome 15 occurs within the PML gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The translocation results in a",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    fusion gene that contains most of the PML coding sequences, and the DNA binding and ligand binding domains of the RARA gene. The",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    fusion protein shows reduced sensitivity to retinoic acid in terms of dissociation of N-CoR, a ubiquitous nuclear protein that mediates transcriptional repression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. This could lead to persistent transcriptional repression, thereby preventing differentiation of promyelocytes. This effect can be overcome by pharmacologic doses of all-trans retinoic acid (ATRA, tretinoin), resulting in relief from transcriptional repression and presumably activating genes that lead to terminal differentiation of promyelocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APL is a unique clinicopathological entity characterized by the infiltration of the bone marrow by promyelocytes in association with clinical or laboratory evidence of disseminated intravascular coagulation (DIC) and fibrinolysis, which may worsen during the initial cytolytic response to chemotherapy. A characteristic folded, reniform (kidney-shaped), or bilobed nucleus is invariably found in some of the promyelocytes; coarse azurophilic granules and multiple Auer rods are also common (",
"    <a class=\"graphic graphic_picture graphicRef82863 \" href=\"mobipreview.htm?2/11/2224\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/24,34\">",
"     24,34",
"    </a>",
"    ]. The microgranular variant of APL differs from the more frequent hypergranular type in that the cytoplasmic granules in the leukemia cells are smaller and sometimes beneath the limit of resolution of the light microscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/24,34\">",
"     24,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from DIC. It is critical to start treatment with ATRA without delay as soon as the diagnosis is",
"    <strong>",
"     suspected",
"    </strong>",
"    based upon cytologic criteria, and before definitive cytogenetic confirmation of the diagnosis. The leukemic cells in patients with APL are exquisitely sensitive to the differentiating effect of ATRA. Patients with APL have an excellent prognosis when ATRA and chemotherapy are begun promptly. The",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    gene can now be routinely identified within 24 hours by PCR methods, allowing confirmation of the diagnosis of APL.",
"   </p>",
"   <p>",
"    Several variant chromosome translocation involving RARA, but not PML have been identified in APL, such as the t(5;17), and t(11;17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. When the",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    fusion is not confirmed in PCR reactions in a patient with suspected APL, FISH analysis with a RARA break-apart probe can provide information as to whether one of these rare translocations is present. Cases of APL that lack the t(15;17) do not respond to ATRA; the",
"    <span class=\"nowrap\">",
"     PLZF/RARA",
"    </span>",
"    fusion protein that is produced in the t(11;17) rearrangement in rare cases shows reduced sensitivity to retinoic acid that cannot be overcome by pharmacologic doses of ATRA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993131070\">",
"    <span class=\"h3\">",
"     Inv(16) and t(16;16)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of chromosome 16 are seen in approximately 7 percent of adults with newly diagnosed AML (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. These abnormalities can be broadly divided into two groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AML with the inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (previously acute myelomonocytic leukemia, AMML, FAB M4Eo) (",
"      <a class=\"graphic graphic_picture graphicRef58646 \" href=\"mobipreview.htm?17/14/17633\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71045 \" href=\"mobipreview.htm?18/62/19424\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      AML with other abnormalities of chromosome 16.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This distinction is made because patients with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) have a favorable prognosis with standard therapy, whereas those with other abnormalities of chromosome 16 do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, the identification of the inv(16)(p13.1q22) or t(16;16)(p13.1;q22) is diagnostic of AML without regard to the bone marrow blast count and has implications for therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H649833351#H649833351\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'General'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AML with inv(16) typically demonstrates monocytic and granulocytic differentiation with abnormal eosinophils in the bone marrow. In the early 1980s, an association between what was previously called acute myelomonocytic leukemia (AMML, AML-M4), excess or morphologically abnormal bone marrow eosinophils (M4Eo), and an abnormal chromosome 16 was first noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Different abnormalities in chromosome 16 were identified in these reports including a pericentric inversion of chromosome 16, inv(16)(p13.1q22) (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ); or a reciprocal translocation involving both chromosome 16 homologs, t(16;16)(p13.1;q22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Patients with these abnormalities had abnormal marrow eosinophils but usually not an excess of eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Among patients with AML-M4 in a University of Chicago series, 23 percent had an inv(16) or t(16;16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/44\">",
"     44",
"    </a>",
"    ]. Similar findings were noted at the Fourth International Workshop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9\">",
"     9",
"    </a>",
"    ]. Among 25 patients with AML-M4 and more than 5 percent marrow eosinophils, 10 had an abnormality of chromosome 16.",
"   </p>",
"   <p>",
"    The inversion breakpoint at 16q22 occurs near the end of the coding region of the core binding factor beta (CBFB) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/45\">",
"     45",
"    </a>",
"    ], which encodes one subunit of the heterodimeric",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB",
"    </span>",
"    transcription factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/15\">",
"     15",
"    </a>",
"    ]. As described above, this transcription factor binds directly to an enhancer core motif that is present in the transcriptional regulatory regions of a number of genes that are critical to myeloid cell growth, differentiation, and function. (See",
"    <a class=\"local\" href=\"#H7\">",
"     '8;21 translocation in AML'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A smooth muscle myosin heavy chain gene (MYH11) is interrupted by the breakpoint on 16p. A fusion protein is produced containing the 5' region of CBFB (165 of 182 amino acids), including the domain that heterodimerizes with RUNX1, fused to the 3' portion of MYH11 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This portion of MYH11 contains a repeated alpha helical structure involved in myosin filament interactions and may therefore be important in dimerization of the fusion protein in leukemia cells. The",
"    <span class=\"nowrap\">",
"     CBFB/MYH11",
"    </span>",
"    fusion protein appears to act by disrupting the function of the",
"    <span class=\"nowrap\">",
"     RUNX1/CBFB",
"    </span>",
"    transcription factor, resulting in the repression of transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/47\">",
"     47",
"    </a>",
"    ]. Transgenic mice expressing the mutant protein have impaired neutrophilic maturation and granulocytic dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the M4Eo syndrome characteristic of CBFB-MYH11, the bone marrow demonstrates abnormalities of the eosinophils in addition to the typical morphologic features of AML. In particular, the eosinophils are seen at all stages of maturation with no significant signs of maturation arrest, but with immature eosinophilic granules seen in the promyelocyte and myelocyte stages of development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. These immature granules are typically larger than normal and purple-violet in color. They may be so prominent that they obscure the cell morphology. The breakpoints at both 16p13.1 and 16q22 are required for manifestation of the complete M4Eo syndrome, since rare patients with only del(16)(q22) have had different morphological and clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/44\">",
"     44",
"    </a>",
"    ]. Conversely, while these morphologic changes are typical for this disorder, some patients with the",
"    <span class=\"nowrap\">",
"     CBFB/MYH11",
"    </span>",
"    fusion gene do not have these abnormalities in most of their bone marrow eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with inv(16) or t(16;16) have a good response to intensive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10,28,44\">",
"     10,28,44",
"    </a>",
"    ]. As an example, an analysis of 5876 younger adults with newly diagnosed AML reported that one of these two abnormalities was seen in 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with inv(16) or t(16;16) had rates of complete remission and 10-year survival of 92 and 55 percent, respectively. Corresponding rates for patients with a normal karyotype were 90 and 38 percent, respectively. Reverse transcription polymerase chain reaction (RT-PCR) can be used to monitor patients for residual disease; however, this technique is so sensitive that patients may remain in continuous clinical remission despite the apparent persistence of small numbers of cells with the fusion transcript [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993131111\">",
"    <span class=\"h3\">",
"     Rearrangements of 11q23",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rearrangements of 11q are seen in approximately 6 percent of young adults with newly diagnosed AML and up to 12 percent of children with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. These rearrangements of 11q were first noted to be common (35 percent) in patients with what was previously called acute monoblastic leukemia (AMoL, AML-M5) and were associated with poorly differentiated monoblasts (AML-M5a) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/51\">",
"     51",
"    </a>",
"    ]. This association with M5a was particularly strong in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9,52\">",
"     9,52",
"    </a>",
"    ]. Later reports identified rearrangements involving chromosome 11 band q23 in about 35 percent of patients with M5 and in almost 50 percent of those with M5a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/51,53-55\">",
"     51,53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three general observations have been made concerning translocations involving chromosome 11q23:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are over 100 different recurring rearrangements that involve 11q23, and 64 translocation partner genes have been cloned, with many different translocation partners in AML, especially the monoblastic and myelomonocytic types [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/2,28,54-56\">",
"       2,28,54-56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These translocations occur in both myeloid and lymphoid leukemias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/24,57,58\">",
"       24,57,58",
"      </a>",
"      ]. A common translocation in infants, t(4;11)(q21;q23), usually has a lymphoblastic phenotype, but the leukemia cells may express some myeloid surface markers and variable numbers of monocytoid blast cells may be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/24,59\">",
"       24,59",
"      </a>",
"      ]. These and other observations suggest that a gene at 11q23 may be involved in determining the differentiation of primitive hematopoietic stem cells into lymphoblasts or monoblasts, or that the gene may be active in both cell lineages. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link\">",
"       \"Cytogenetics in acute lymphoblastic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Translocations involving 11q23 have an unusual age distribution, accounting for about three-quarters of the chromosomal abnormalities observed in leukemia cells of infants under one year of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/55,60,61\">",
"       55,60,61",
"      </a>",
"      ]. These leukemias are either myelomonocytic or monocytic (AML-M4 and AML-M5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/60\">",
"       60",
"      </a>",
"      ] or acute lymphoblastic leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Translocations of 11q23 involve the MLL gene",
"    <span class=\"nowrap\">",
"     (myeloid/lymphoid,",
"    </span>",
"    or mixed-lineage, leukemia, also called ALL1 or HRX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/57,58,63,64\">",
"     57,58,63,64",
"    </a>",
"    ]. All known breakpoints fall within an 8.3 kb breakpoint cluster region of the gene encompassing exons 5 to 11. As a result, MLL translocations can be detected by Southern blot analysis of DNA using a small cDNA probe containing these exons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MLL protein contains one potential DNA-binding motif (AT-hooks), a transcriptional activation domain in the COOH-terminus, and a repression domain in the N-terminal portion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/65\">",
"     65",
"    </a>",
"    ]. The MLL protein has homology to the Drosophila trithorax gene product, a transcription factor that regulates embryonic development and tissue differentiation in this organism. MLL is a DNA-binding protein that methylates histone H3 lysine 4 (H3K4), and positively regulates gene expression by binding to open chromatin structures at the active promoter regions of various genes, including multiple Hox genes, that are important in hematopoietic and lymphoid cell development, including myelomonocytic differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Translocations of MLL result in the formation of a chimeric gene on the derivative 11 chromosome, consisting of the 5' region of MLL and the 3' region of the partner gene from the other chromosome, with subsequent expression of fusion mRNAs. The most common translocation involves MLL and the MLLT3 (AF9) gene at 9p22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. The AT hook DNA-binding motif and repression domain are retained in the fusion protein, but the strong activation domain is lost, leading to the absence of the H3K4 methyltransferase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/65,69\">",
"     65,69",
"    </a>",
"    ]. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. It has been presumed that altered MLL function contributes to leukemogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/72\">",
"     72",
"    </a>",
"    ], but the partner gene also appears to be important. Consistent with this hypothesis is the observation that AML occurs in chimeric mice containing an",
"    <span class=\"nowrap\">",
"     MLL/AF9",
"    </span>",
"    fusion gene from a t(9;11), but not in mice with a disrupted MLL gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/69\">",
"     69",
"    </a>",
"    ]. At least four groups of MLL partner genes with various putative functions have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nuclear proteins AFF1 (AF4), MLLT3 (AF9), MLLT10 (AF10), MLLT1 (ENL) and OCEL1 (ELL) have putative DNA-binding functions.",
"     </li>",
"     <li>",
"      CREB binding protein (CBP) and EP300 (P300) are histone acetyltransferases.",
"     </li>",
"     <li>",
"      FOXO (AFX) and MLLT4 (AF6) contain the coil-coil oligomerization domains.",
"     </li>",
"     <li>",
"      SEPT2, SEPT5, SEPT6, SEPT9 and SEPT11 belong to the Septin family that interacts with cytoskeletal filaments during the mitosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be that the genes on the partner chromosomes interact with MLL to yield either the myeloid or the lymphoid phenotype of the corresponding leukemia. The leukemias associated with the",
"    <span class=\"nowrap\">",
"     MLL/AF9",
"    </span>",
"    fusion gene in mice appear to be preceded by an initial stage of nonmalignant expansion of myeloid precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/73\">",
"     73",
"    </a>",
"    ]. It was suggested that a \"second hit\" was required for malignant transformation and that the myeloproliferation provided the pool of cells in which this event can occur. On the other hand, the",
"    <span class=\"nowrap\">",
"     MLL/AF4",
"    </span>",
"    fusion gene associated with t(4;11)(q21;q23) is associated with acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another association has been described between defects in the MLL gene and AML. A molecular rearrangement leading to a partial tandem duplication of the MLL gene has been found in 11 percent of patients with AML and a normal karyotype and in approximately 90 percent of adults with AML who have trisomy 11 as the only karyotypic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, only a single mutated allele with a partial tandem duplication appears to be sufficient for leukemogenesis.",
"   </p>",
"   <p>",
"    In general, leukemia patients with",
"    <span class=\"nowrap\">",
"     11q23/MLL",
"    </span>",
"    rearrangements, regardless of myeloid or lymphoid lineage involvement, have a very dismal prognosis, particularly infant ALL patients with the t(4;11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/75\">",
"     75",
"    </a>",
"    ]. In contrast, patients with t(9;11)(p22;q23) tend to have an intermediate response to standard therapy. In the 2008 WHO classification of hematopoietic and lymphoid tissues, the t(9;11) is listed as one of the subcategories of AML with recurring genetic abnormalities. An analysis of 5876 younger adults with newly diagnosed AML reported the t(9;11)(p22;q23) in 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with the t(9;11)(p22;q23) had rates of complete remission and 10-year survival of 84 and 39 percent, respectively. Corresponding rates for patients with a normal karyotype were 90 and 38 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     t(3;3) and inv(3) in AML with thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(3;3) and inv(3) account for approximately 1 percent of AML cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. This abnormality is seen in de novo AML and in therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML.",
"    </span>",
"    Cytogenetic abnormalities of 3q are associated with thrombocytosis in the peripheral blood and increased atypical megakaryocytes in the bone marrow of patients with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. The specific cytogenetic abnormalities involve bands 3q21 and 3q26.2 simultaneously, and they include the inv(3)(q21q26.2), t(3;3)(q21;q26.2), and the ins(5;3)(q14;q21q26.2) (insertion of chromosomal material from 3q into 5q).",
"   </p>",
"   <p>",
"    A study of 6515 adults with newly diagnosed AML enrolled in prospective trials detected 3q abnormalities in 4.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/79\">",
"     79",
"    </a>",
"    ]. Of these,",
"    <span class=\"nowrap\">",
"     t(3;3)/inv(3),",
"    </span>",
"    t(3q26.2), t(3q21), and other 3q abnormalities accounted for 32, 18, 7, and 43 percent, respectively. Patients with",
"    <span class=\"nowrap\">",
"     t(3;3)/inv(3)",
"    </span>",
"    presented with a median platelet count of 144K (range 1K to 234K). Rates of complete response, overall survival at five years and relapse-free survival at five years were 31, 6, and 4 percent, respectively. In 94 patients with AML demonstrating the",
"    <span class=\"nowrap\">",
"     inv(3q)/t(3;3),",
"    </span>",
"    monosomy 7 was the most common additional aberration, and it contributed to the adverse prognostic impact of the inv(3q) t(3;3) on relapse-free survival and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the most consistent bone marrow finding in this disorder is an increase in the number of megakaryocytes, many of which are morphologically abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. In some patients, almost all of the identifiable megakaryocytes are micromegakaryocytes. A few circulating megakaryoblasts may be seen, but these findings alone are not indicative of acute megakaryoblastic leukemia.",
"   </p>",
"   <p>",
"    The t(3;3) and inv(3) abnormalities seen in AML result in the activation of the EVI1 (MECOM) gene, located at 3q26.2. The chromosomal rearrangements that lead to this activation are either 5' of the gene in the t(3;3) or 3' of the gene in the inv(3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/80\">",
"     80",
"    </a>",
"    ]. EVI1 is a transcription factor that contains a seven-zinc-finger domain at the N-terminal end, a three-finger domain in the central part of the molecule, and an acidic domain distal to the second group of zinc fingers. Depending on its binding partners, EVI1 can act as a transcriptional activator to promote the proliferation of hematopoietic stem cells (eg, when bound to GATA2) or as a transcriptional repressor inhibiting erythroid differentiation (eg, when bound to GATA1).",
"   </p>",
"   <p>",
"    Activation of EVI1 in hematopoietic cells can occur by juxtaposition of the gene to enhancer elements of the ribophorin gene located at 3q21 in inv(3)(q21q26.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/81\">",
"     81",
"    </a>",
"    ] and, in the t(3;21)(q26.2;q22), as part of the fusion",
"    <span class=\"nowrap\">",
"     RUNX1/EVI1",
"    </span>",
"    mRNA transcribed from the der(3) chromosome. The leukemogenicity of the fusion gene has been demonstrated by expressing the gene in bone marrow cells; transplanting these cells into mice leads to the development of acute myeloid leukemia 5 to 13 months later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/82\">",
"     82",
"    </a>",
"    ]. Abnormal expression of EVI1 has also been detected in patients with myeloid leukemia and a normal karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/83\">",
"     83",
"    </a>",
"    ], suggesting that inappropriate activation of this gene occurs through various mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/84\">",
"     84",
"    </a>",
"    ], and may confer an adverse prognosis. How abnormalities in EVI1 lead to leukemogenesis is not clear. In vitro studies show that the",
"    <span class=\"nowrap\">",
"     RUNX1/EVI1",
"    </span>",
"    fusion protein blocks neutrophil differentiation and abrogates the growth inhibitory effect of transforming growth factor-beta, thereby allowing cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H649833351#H649833351\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'General'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H20#H20\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Overexpression of EVI1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H983671238\">",
"    <span class=\"h3\">",
"     t(6;9)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML with t(6;9)(p23;q34), DEK-NUP214, is seen in approximately 1 percent of patients with newly diagnosed AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. This subtype of AML typically presents with basophilia, pancytopenia, and dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8,86\">",
"     8,86",
"    </a>",
"    ]. In a retrospective series of 69 patients with t(6;9), this translocation was detected as the sole abnormality in about 88 percent of cases analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/87\">",
"     87",
"    </a>",
"    ]. The pathological features of AML with the t(6;9) include basophilia, single or multilineage dysplasia in adult patients, variable FAB morphology, a CD13+, CD33+,CD38+,CD45+, and HLA-DR+ phenotype, and a high incidence (71 percent) of FLT3 internal tandem duplications. The translocation results in the juxtaposition of DEK on chromosome 6 with NUP214 (also known as CAN) on chromosome 9. This results in the creation of a nucleoporin fusion protein that acts as a transcription factor and also alters nuclear transport. Patients with the t(6;9)(p23;q34) typically have a poor outcome with standard therapy. An analysis of 5876 younger adults with newly diagnosed AML reported that DEK-NUP214 was seen in one percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. These patients had rates of complete remission and 10-year survival of 88 and 27 percent, respectively. Corresponding rates for patients with a normal karyotype were 90 and 38 percent, respectively. This translocation may not be an independent predictor of prognosis, but rather the poor outcomes seen in this population may reflect the higher than normal prevalence of FLT3-ITD mutations (70 percent), which are known to convey a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'FLT3 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H983671253\">",
"    <span class=\"h3\">",
"     t(1;22)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML with the t(1;22)(p13;q13), RBM15-MKL1, is a rare entity accounting for &lt;0.5 percent of cases of newly diagnosed AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. It is typically a megakaryoblastic process occurring in infants, although it is not seen in patients with Down syndrome. Sometimes it can present as a mass and mimic sarcoma. This translocation involves the RNA-binding motif protein-15 (RBM15, also known as OTT) and a DNA binding motif protein known as megakaryocyte leukemia-1 (MKL1, also known as MAL). MKL1 is involved in the normal production of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. The role of the resultant chimeric protein in leukemogenesis is poorly understood, but may include the modulation of chromatin organization, HOX-induced differentiation, or extracellular signalling pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of t(1;22)(p13;q13) with modern therapy is unclear. An analysis of 5876 younger adults with newly diagnosed AML reported that t(1;22)(p13;q13) was seen in only one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. Because of the rarity of this translocation, the study was unable to comment on prognosis. Other reports on prognosis have had mixed results with some suggesting low survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/92,93\">",
"     92,93",
"    </a>",
"    ] and others reporting long term remission after intensive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993128835\">",
"    <span class=\"h2\">",
"     Chromosomal gain and loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to chromosomal translocations, there is a recurring pattern of gain or loss of specific chromosomes in patients with AML. The number of chromosomes gained or lost in 354 patients with AML and a clonal abnormality was examined at the Fourth International Workshop on Chromosomes in Leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9\">",
"     9",
"    </a>",
"    ]. Each of the chromosomes could be affected, but there was a variable frequency. Some chromosomes were more likely to have a gain or loss. The most common abnormalities were a gain of chromosome 8 (trisomy 8, 13 percent), loss of chromosome 7 (9 percent), and loss of chromosome 5 (6 percent). A gain of chromosomes 7 or 5 was rarely observed. Abnormalities of chromosomes 5 and 7 are particularly characteristic of therapy-related AML induced by alkylating agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/3,4,8\">",
"     3,4,8",
"    </a>",
"    ]. How these deletions might promote myeloid leukemogenesis is described below (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Mechanisms of dysplasia and leukemogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Deletions of the short arm of chromosome 17 have also been described in AML or myelodysplastic syndrome, usually as part of an unbalanced chromosomal translocation, most often involving chromosome 5, and resulting in a dicentric chromosome: dic(5;17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The 17p deletion typically involves loss of the TP53 tumor suppressor gene.",
"   </p>",
"   <p>",
"    Chromosomal gains and losses are seen in most subtypes of AML, although there are some differences in frequency, and certain abnormalities are seen with specific disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9,26,97,98\">",
"     9,26,97,98",
"    </a>",
"    ]. As an example, one series of 26 patients with acute erythroblastic leukemia (FAB-M6) found clonal abnormalities in 20 (77 percent), 17 of whom had loss of all or part of chromosome 5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/99\">",
"     99",
"    </a>",
"    ]. In addition, the karyotypes were often complex with multiple abnormalities and subclones. The patients with complex karyotypes were older than those with normal karyotypes or simple chromosomal changes, had a shorter survival, and had biologic and clinical features similar to those seen in therapy-related AML. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Loss of the Y chromosome, the second most frequent numerical change in the patients examined at Fourth International Workshop, or loss of one X chromosome usually occurred in association with an 8;21 translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9\">",
"     9",
"    </a>",
"    ]. Loss of the Y chromosome can also be the sole abnormality. However, the significance of this finding is uncertain because a missing Y chromosome has been described in bone marrow cells of hematologically normal men, particularly those over 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/1,100\">",
"     1,100",
"    </a>",
"    ]. In contrast, the t(8;21) in acute myeloid leukemia with maturation (AML-M2, also called acute myeloblastic leukemia) is usually observed in younger adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/6,9,26,27,100\">",
"     6,9,26,27,100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     '8;21 translocation in AML'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantial body of evidence supporting an association between environmental factors and the development of AML with clonal chromosomal abnormalities. An initial retrospective study evaluated 162 Swedish patients with AML de novo; 52 gave a history of occupational exposure to chemical solvents, insecticides, or petroleum products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/101\">",
"     101",
"    </a>",
"    ]. Clonal chromosomal abnormalities were much more common in the patients exposed to solvents and insecticides than in those exposed to petrol products or with no exposure (92 versus 29 and 32 percent). This association did not appear to occur by chance, since 79 percent of the exposed patients with chromosomal changes had at least one of four specific abnormalities:",
"    <span class=\"nowrap\">",
"     -5/del(5q),",
"    </span>",
"    <span class=\"nowrap\">",
"     -7/del(7q),",
"    </span>",
"    +8, or +21. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Chemical exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other reports have found similar associations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. In addition to karyotypic abnormalities, proto-oncogene activation also may be related to environmental exposures. Oncogenic RAS mutations have been implicated in the pathogenesis of some types of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. In a report from the Cancer and Leukemia Group B, for example, patients with a RAS gene mutation in AML were more likely than patients with RAS mutation negative AML to have breathed chemical vapors at work (odds ratio 9.1) or to have had skin contact with chemicals (odds ratio 6.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/104\">",
"     104",
"    </a>",
"    ]. Patients with RAS mutation negative AML were not more likely than controls to have had these exposures. The risk for AML also is increased by previous exposure to cytotoxic therapy and perhaps to smoking and alcohol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/103,110\">",
"     103,110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H4#H4\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'RAS oncogene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THERAPY-RELATED MYELOID NEOPLASMS (T-MDS/T-AML)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic chromosomal abnormalities have also been identified in patients who developed a myelodysplastic syndrome (MDS) or AML after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for an earlier disorder, such as Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), carcinoma, rheumatoid arthritis, or organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/111-116\">",
"     111-116",
"    </a>",
"    ]. Therapy-related AML (t-AML), therapy-related MDS (t-MDS), and therapy-related myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (t-MDS/MPN)",
"    </span>",
"    lie along a continuum of disease and are categorized by the 2008 WHO classification system as therapy-related myeloid neoplasms (t-MN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/8\">",
"     8",
"    </a>",
"    ]. T-MN can also occur following the treatment of AML and this is becoming a more widely recognized event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Thus, it is important to perform cytogenetic analysis at the time of AML relapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\", section on 'Cytotoxic agents that have been implicated'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clonal chromosomal abnormalities are usually present in t-MDS prior to the evolution to leukemia, and these changes are often multiple and complex. Thus, detection of a clonal abnormality in a pancytopenic patient provides strong evidence of a malignant secondary neoplasm, even though the percentage of blasts in the marrow may not yet be elevated. Morphologic evaluation of the marrow alone is often hindered by the persistence of the primary disorder, such as myeloma or low grade lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link&amp;anchor=H4#H4\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an informative study, 29 of 230 patients with a primary diagnosis of NHL developed t-MN following high dose therapy (HDT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus total-body irradiation, followed by autologous stem cell transplantation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/119\">",
"     119",
"    </a>",
"    ]. Significant levels of clonally abnormal cells were found",
"    <strong>",
"     prior to HDT",
"    </strong>",
"    in all 20 of the patients in whom this material was available. In contrast, such abnormalities were seen prior to HDT in only three of 24 similarly treated patients who currently have not developed t-MN at a median follow-up of 5.9 years after HDT. This study suggests that the presence of clonal abnormalities prior to HDT may predict those at risk for t-MN, and may be a rationale for the use of less leukemogenic conditioning regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subsets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical and biological subsets of t-MN have been recognized, and these are correlated with the specific therapy administered for the primary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Following alkylating agents and/or radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of t-MN is due to damage from alkylating agents. The alkylating agents react directly with DNA, inducing t-MN with unbalanced aberrations, primarily loss of chromosome material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/120\">",
"     120",
"    </a>",
"    ]. Involvement of chromosomes 5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    7 are characteristic of this subtype of therapy-related disease (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/111,113,116,120-123\">",
"     111,113,116,120-123",
"    </a>",
"    ], and may be related to polymorphisms in enzymes responsible for modifying host responses to damage caused by leukemogens such as benzene and alkylating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/124-126\">",
"     124-126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Chemical exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 63 patients with t-MN from the University of Chicago, 61 had clonal cytogenetic abnormalities (95 percent). An abnormal karyotype with loss of all or part of chromosomes 5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    7 was observed in 55 (87 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/122\">",
"     122",
"    </a>",
"    ]. This pattern has persisted as the Chicago series has reached 306 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/127\">",
"     127",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormalities of chromosomes 5",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      7 &mdash; 70 percent",
"     </li>",
"     <li>",
"      Monosomy chromosome 7, or del(7q) &mdash; 50 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       -5/del(5q)/t(5q)",
"      </span>",
"      &mdash; 43 percent",
"     </li>",
"     <li>",
"      Normal karyotype &mdash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some specific translocations also occur in t-MN following multiagent chemotherapy. As an example, the NUP98 gene, which encodes a component of the nucleoporin complex, is located at 11p15; this site is the breakpoint for three distinct chromosomal rearrangements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. Mutations and loss of heterozygosity of the TP53 tumor suppressor gene, located on chromosome band 17p13, are also seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/130\">",
"     130",
"    </a>",
"    ]. In one study of 77 patients with t-MN, somatically acquired mutations of TP53 were observed in 21 (27 percent); 19 of these 21 patients had received alkylating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/131\">",
"     131",
"    </a>",
"    ]. Mutations of TP53 are associated with abnormalities of chromosome 5 and a complex karyotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Following DNA topoisomerase II inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second subtype of t-MN occurs in patients who have been treated with chemotherapeutic drugs that inhibit DNA topoisomerase II (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Balanced translocations occur in this type of t-MN, and most often involve the MLL gene at 11q23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/132\">",
"     132",
"    </a>",
"    ] or the RUNX1 gene at 21q22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/116,120,123,133,134\">",
"     116,120,123,133,134",
"    </a>",
"    ]. Another recurring translocation that also involves the MLL gene, t(11;16)(q23;p13.3), has been described only in t-MN following exposure to a topoisomerase II inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/135,136\">",
"     135,136",
"    </a>",
"    ]. Patients with this translocation may present with a MDS, which is rarely seen with other 11q23 translocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/136\">",
"     136",
"    </a>",
"    ]. The fusion gene with t(11;16)(q23;p13.3) consists of MLL fused to the gene that encodes CREB-binding protein (CREBBP or CBP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/135\">",
"     135",
"    </a>",
"    ]. The fusion product retains the histone acetyltransferase domain of CREB binding protein; this may promote leukemogenesis by inducing histone acetylation of genomic regions targeted by MLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topoisomerase II inhibitor therapy has also been associated with t(15;17)(q22;q21.1) and acute promyelocytic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/138-141\">",
"     138-141",
"    </a>",
"    ], as well as t(4;11) and acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1052370514\">",
"    <span class=\"h3\">",
"     Following bimolane for psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bimolane has been used to treat psoriasis outside of the United States and has been associated with the development of t-MN. T-MN is less common after bimolane than after alkylating agents. Most forms of AML can occur, but the most common is acute promyelocytic leukemia (AML-M3) with its characteristic t(15;17) (",
"    <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mechanisms of dysplasia and leukemogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high frequency of loss of 5q",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    7q in t-MN due to alkylating agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (and less often in de novo disease) suggests that critical genes located at these sites are related to myelodysplasia and myeloid leukemogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/143,144\">",
"     143,144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     del(5q)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic and molecular analysis of MDS, AML and t-AML with a del(5q) has resulted in the identification of a region of approximately 1 Mb that is deleted in all patients (referred to as the commonly deleted segment) proposed to contain critically important genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/144-147\">",
"     144-147",
"    </a>",
"    ]. A second, distal commonly deleted segment has been identified in 5q32-q33.1 in patients with MDS with an isolated del(5q) (5q- syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/148\">",
"     148",
"    </a>",
"    ]. A number of genes located on 5q including RPS14, EGR1, NPM1, APC, and CTNNA1 have been implicated in the development of myeloid disorders due to a gene dosage effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/149\">",
"     149",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The gene encoding RPS14 located in 5q32, which is required for the processing of 18S pre-rRNA, was identified as a candidate disease gene in the 5q- syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/150\">",
"     150",
"    </a>",
"    ]. Downregulation of RPS14 in CD34+ bone marrow cells blocks the differentiation of erythroid cells, and increases apoptosis in differentiating erythroid cells in vitro. Studies in a mouse model suggest that a TP53-dependent mechanism underlies this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/151\">",
"     151",
"    </a>",
"    ]. Of interest, the ribosomal processing defect caused by haploinsufficiency of RPS14 in the 5q- syndrome is highly analogous to the functional ribosomal defect seen in Diamond-Blackfan anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies have shown that haploinsufficiency of two micro-RNAs (miRNAs) that are abundant in hematopoietic",
"    <span class=\"nowrap\">",
"     stem/progenitor",
"    </span>",
"    cells (HSPCs), miR-145 and miR-146a, are encoded by sequences near the RPS14 gene, and cooperate with loss of RPS14. The Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP) and tumor necrosis factor receptor-associated factor-6 (TRAF6) are respective targets of these miRNAs, implicating inappropriate activation of innate immune signals in the pathogenesis of the 5q- syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/152,153\">",
"     152,153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genes located on 5q that are deleted in MDS, AML, or therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    with a del(5q) include EGR1, NPM1, CTNNA1, and APC. Loss of function of Apc (adenomatosis polyposis coli gene, Apc tumor suppressor gene) in animal models produces a condition simulating MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/154\">",
"     154",
"    </a>",
"    ]. Similarly, loss of function of EGR1 cooperates with mutations induced by alkylating agents to induce myeloid neoplasms in mouse models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/155\">",
"     155",
"    </a>",
"    ]. Loss of expression of the alpha-catenin (CTNNA1) gene in hematopoietic stem and progenitor cells, as a result of chromosomal deletion or epigenetic silencing, may also contribute to transformation of myeloid cells in AML patients with a del(5q) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/156\">",
"     156",
"    </a>",
"    ]. Although Npm1 heterozygous mice",
"    <span class=\"nowrap\">",
"     (Npm1+/-)",
"    </span>",
"    develop erythroid dysplasia and dysplastic megakaryocytes, the role of NPM1 in the pathogenesis of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    is unclear, since NPM1 is neither deleted in many patients with a del(5q), nor have mutations been identified in the remaining allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/157\">",
"     157",
"    </a>",
"    ]. These results provided support to the current model that the cooperative loss of multiple genes on 5q is required for the pathogenesis of myeloid disorders with a del(5q).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     del(7q)",
"    </span>",
"    &nbsp;&mdash;&nbsp;To determine the location of genes on 7q that may be involved in myelodysplasia and myeloid leukemogenesis, the breakpoints and the extent of the del(7q) were evaluated in 55 patients with primary MDS or de novo AML and in 26 patients with t-MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/158\">",
"     158",
"    </a>",
"    ]. This analysis suggested that there may be two distinct deleted segments of chromosome 7. The majority of patients had proximal breakpoints in q11.2-22 and distal breakpoints in q22-36. The smallest overlapping deleted segment was within q22. A minority of patients had involvement of q31-36, with a commonly deleted segment consisting of q32-33.",
"   </p>",
"   <p>",
"    FISH was used to define the deleted segment at 7q22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/158\">",
"     158",
"    </a>",
"    ]. The commonly deleted segment was 2 to 3 Mb; a slightly more distal, but an overlapping, commonly deleted segment was identified in 7q in another report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/159\">",
"     159",
"    </a>",
"    ]. An overlapping, but slightly proximal, commonly deleted segment was identified, which contains the gene encoding the transcription factor CUX1, hypothesized to act as a tumor suppressor by regulating genes that promote hematopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/160\">",
"     160",
"    </a>",
"    ]. Patients with de novo or therapy-related malignant myeloid disorders with del(7q) demonstrate haploinsufficiency for CUX1. Further study is needed to determine whether haploinsufficiency of CUX1 is sufficient for the development of myeloid malignancies, or whether haploinsufficiency of additional genes on 7q are necessary. Patients with the less frequent loss of band 7q32 have a very poor prognosis, suggesting that critical genes may be present at this site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microarray-based studies of MDS and myeloproliferative neoplasma (MPN) have implicated another region on 7q, band 7q36, in the pathogenesis of these diseases. These studies revealed the presence of acquired uniparental disomy (aUPD, or acquired copy-neutral loss of homozygosity) in some cases. Further analysis led to the identification of rare patients with microdeletions and the subsequent identification of mutations in the EZH2 gene within the deleted segment. Homozygous EZH2 mutations are found in approximately 75 percent of patients with aUPD, and in 12 percent of patients with",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    (both monoallelic and biallelic mutations were detected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. Notably, these patients typically do not have cytogenetically visible abnormalities of chromosome 7. EZH2 encodes the catalytic subunit of the polycomb repressive complex 2 (PRC2), a highly conserved histone H3 lysine 27 (H3K27) methyltransferase that influences stem cell renewal by epigenetic repression of genes involved in cell fate decisions. EZH2 was previously reported to be an oncogene in epithelial tumors, such as breast cancer; however, the mutations identified in",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    result in loss of function of the histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H826365\">",
"    <span class=\"h2\">",
"     AML following immunosuppressive and growth factor therapy for aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of acquired aplastic anemia are at increased risk for AML. Development of these disorders has been associated with the acquisition of monosomy 7 and concerns have been raised about a possible contributory role from long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) therapy, perhaps in combination with immunosuppressive therapy. In one study of 72 adults with aplastic anemia, MDS developed in 1 of 47 patients treated without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or antithymocyte globulin compared with 4 of 25 treated with one or the other of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/164\">",
"     164",
"    </a>",
"    ]. All four had received long-term G-CSF at a higher cumulative dose than those who did not develop a myelodysplastic syndrome. Administration of G-CSF for more than one year was the single most important risk factor for the development of MDS in these patients. Similar results were noted in another study in which myeloid neoplasms developed in 11 of 50 children with acquired aplastic anemia who were treated with cyclosporine and G-CSF compared with none of 41 treated with either agent alone and none of 48 who underwent bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/165\">",
"     165",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H727300840#H727300840\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Exogenous growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H826661\">",
"    <span class=\"h1\">",
"     AML WITH NORMAL KARYOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to AML with recurring balanced translocations, and chromosomal gains and losses described above, about 40 to 50 percent of de novo AML and up to 10 percent of t-AML will have a normal karyotype by conventional cytogenetic analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/1\">",
"     1",
"    </a>",
"    ]. This is a very heterogeneous group of patients with variable age, morphological features, and clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10,166\">",
"     10,166",
"    </a>",
"    ]. In a study of 5876 young adults with newly diagnosed de novo or secondary AML, 41 percent of patients had a normal karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"     10",
"    </a>",
"    ]. These patients had rates of complete remission and 10-year survival of 90 percent and 38 percent, respectively.",
"   </p>",
"   <p>",
"    Using genomic microarray analysis, and other molecular techniques, many novel gene mutations have been identified in normal karyotype AML. These include",
"    <span class=\"nowrap\">",
"     FLT3-ITD/TKD",
"    </span>",
"    and MLL-PTD, as well as mutations of NPM1, NRAS CEBPA, BAALC, and WT1. Identification of these mutations provides new insights into the pathogenesis of this group of AML with a normal karyotype, and it also is important in further clarifying prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727305333\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic analysis of metaphase cells is a key component in the evaluation of all patients with newly diagnosed or suspected acute myeloid leukemia (AML). Specific cytogenetic abnormalities are closely, and sometimes uniquely, associated with morphologically and clinically distinct subsets of the disease. As such, the 2008 WHO classification of tumors of the hematopoietic and lymphoid tissues uses genetic findings in addition to morphologic, immunophenotypic, and clinical features to define distinct subtypes of AML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p>",
"    Using standard banding techniques, 50 to 60 percent of patients with AML de novo have abnormal karyotypes. The most common abnormalities seen on karyotype are t(15;17)(q24.1;q21.1), trisomy 8, t(8;21)(q22;q22),",
"    <span class=\"nowrap\">",
"     inv(16)(p13.1q22)/t(16;16)(p13.1;q22),",
"    </span>",
"    and 11q rearrangements. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Acute myeloid leukemia de novo'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following cytogenetic abnormalities, if found, result in the diagnosis of AML regardless of blast count:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AML with the t(8;21)(q22;q22); RUNX1-RUNX1T1 (previously AML1-ETO) &mdash; This translocation is seen in approximately 7 percent of adults with newly diagnosed AML and is the most frequent abnormality in children with AML. The RUNX1 (previously AML1 or core binding factor alpha-2) gene on chromosome 21 and the RUNX1T1 (previously ETO or MTG8) gene on chromosome 8 form a chimeric product that regulates the transcription of a number of genes that are critical to hematopoietic stem and progenitor cell growth, differentiation, and function. Cases of AML with the t(8;21) have a morphologically distinct phenotype. It portends a favorable prognosis in adults, but a poor prognosis in children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       '8;21 translocation in AML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AML with the inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 &mdash; AML with inv(16) represents approximately 5 percent of newly diagnosed AML and typically demonstrates monocytic and granulocytic differentiation with abnormal eosinophils in the bone marrow. The resultant",
"      <span class=\"nowrap\">",
"       CBFB/MYH11",
"      </span>",
"      fusion protein disrupts the function of the",
"      <span class=\"nowrap\">",
"       RUNX1/CBFB",
"      </span>",
"      transcription factor, resulting in the repression of transcription. Patients with inv(16) generally have a good response to intensive chemotherapy. (See",
"      <a class=\"local\" href=\"#H993131070\">",
"       'Inv(16) and t(16;16)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      APL with t(15;17)(q24.1;q21.1); PML-RARA &mdash; This translocation is highly specific for acute promyelocytic leukemia (APL) and results in a",
"      <span class=\"nowrap\">",
"       PML/RARA",
"      </span>",
"      fusion protein that is thought to lead to persistent transcriptional repression, thereby preventing differentiation of promyelocytes. APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from disseminated intravascular coagulation. It is critical to start treatment as the diagnosis is",
"      <strong>",
"       suspected",
"      </strong>",
"      based upon cytologic criteria, and before definitive cytogenetic confirmation of the diagnosis. Patients with APL have an excellent prognosis when appropriate treatment is begun promptly. (See",
"      <a class=\"local\" href=\"#H8\">",
"       '15;17 translocation in APL'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"       \"Molecular biology of acute promyelocytic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following four AML subtypes, which require at least 20 percent myeloid blasts for diagnosis, have been identified as subcategories of AML with genetic abnormalities of prognostic significance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AML with t(9;11)(p22;q23); MLLT3-MLL &mdash; There are over 100 different recurring rearrangements that involve 11q23, with many different translocation partners in AML, especially the monoblastic and myelomonocytic types. The t(9;11) is the most common and involves the MLL gene and MLLT3 (AF9). These patients tend to have an intermediate response to standard therapy. (See",
"      <a class=\"local\" href=\"#H993131111\">",
"       'Rearrangements of 11q23'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AML with t(6;9)(p23;q34); DEK-NUP214 &mdash; This abnormality is seen in approximately 1 percent of patients with newly diagnosed AML and in cases with this translocation are characterized by basophilia, pancytopenia, and dysplasia. Patients with this abnormality have a poor response to standard therapy, which may be a result of the lesion itself or its association with FLT3-ITD, which is also known to convey a poor prognosis. (See",
"      <a class=\"local\" href=\"#H983671238\">",
"       't(6;9)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 &mdash; The t(3;3) and inv(3) account for approximately 1 percent of AML cases and are associated with a poor response to therapy. These cytogenetic changes lead to the activation of the EVI1 gene, which is thought to result in the peripheral blood thrombocytosis and increased atypical megakaryocytes in the bone marrow characteristic of cases with this abnormality. (See",
"      <a class=\"local\" href=\"#H11\">",
"       't(3;3) and inv(3) in AML with thrombocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 &mdash; This type of leukemia is also rare, but is typically a megakaryoblastic process occurring in infants, although it is not seen in patients with Down syndrome. The prognostic significance of t(1;22)(p13;q13) with modern therapy is unclear. (See",
"      <a class=\"local\" href=\"#H983671253\">",
"       't(1;22)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristic chromosomal abnormalities have also been identified in patients who developed a myelodysplastic syndrome (MDS) or AML after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for an earlier disorder. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common type of therapy-related",
"      <span class=\"nowrap\">",
"       MDS/AML",
"      </span>",
"      is due to damage from alkylating agents and is characterized by abnormalities in chromosomes 5",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      7 (",
"      <a class=\"graphic graphic_figure graphicRef53821 \" href=\"mobipreview.htm?2/1/2073\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Following alkylating agents and/or radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second most common subtype of therapy-related AML occurs in patients who have been treated with chemotherapeutic drugs that inhibit DNA topoisomerase II (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      ). AML associated with these drugs is often characterized by balanced translocations involving the MLL gene at 11q23, or the RUNX1 gene at 21q22. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Following DNA topoisomerase II inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Heim S, Mitelman F. Cancer Cytogenetics, 3rd ed, Wiley, Hoboken, NJ 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/2\">",
"      Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997; 15 Spec No:417.",
"     </a>",
"    </li>",
"    <li>",
"     Godley LA, LeBeau MM. Cytogenetics and molecular abnormalities. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Beutler E, et al. (Eds), McGraw-Hill, Burr Ridge, IL 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/4\">",
"      Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/5\">",
"      Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/6\">",
"      Koeffler HP. Syndromes of acute nonlymphocytic leukemia. Ann Intern Med 1987; 107:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/7\">",
"      Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/9\">",
"      The Fourth International Workshop on Chromosomes in Leukemia: A prospective study of acute nonlymphocytic leukemia. Chicago, Illinois, U S A, September 2-7, 1982. Cancer Genet Cytogenet 1984; 71:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/10\">",
"      Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/11\">",
"      Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/12\">",
"      Nucifora G, Birn DJ, Erickson P, et al. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 1993; 81:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/13\">",
"      Kozu T, Miyoshi H, Shimizu K, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/14\">",
"      Corpora T, Roudaia L, Oo ZM, et al. Structure of the AML1-ETO NHR3-PKA(RII&alpha;) complex and its contribution to AML1-ETO activity. J Mol Biol 2010; 402:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/15\">",
"      Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995; 15:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/16\">",
"      Chou FS, Griesinger A, Wunderlich M, et al. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood 2012; 120:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/17\">",
"      Pulikkan JA, Madera D, Xue L, et al. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling. Blood 2012; 120:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/18\">",
"      Crispino JD. JAKing up AML1-ETO. Blood 2012; 120:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/19\">",
"      Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/20\">",
"      Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A 1996; 93:12359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/21\">",
"      Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998; 91:3134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/22\">",
"      Linggi B, M&uuml;ller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/23\">",
"      Fazi F, Zardo G, Gelmetti V, et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 2007; 109:4432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/24\">",
"      Bitter MA, Le Beau MM, Rowley JD, et al. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol 1987; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/25\">",
"      Peniket A, Wainscoat J, Side L, et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol 2005; 129:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/26\">",
"      Larson RA, Le Beau MM, Vardiman JW, et al. The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet 1983; 10:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/27\">",
"      Samuels BL, Larson RA, Le Beau MM, et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/28\">",
"      Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/29\">",
"      Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/30\">",
"      Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/31\">",
"      Muto A, Mori S, Matsushita H, et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/32\">",
"      Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996; 88:3704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/33\">",
"      Satake N, Maseki N, Kozu T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995; 91:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/34\">",
"      Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/35\">",
"      Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/36\">",
"      de Th&eacute; H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/37\">",
"      Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/38\">",
"      Redner RL, Rush EA, Faas S, et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/39\">",
"      Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/40\">",
"      Chen SJ, Zelent A, Tong JH, et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993; 91:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/41\">",
"      Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. Blood 1983; 61:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/42\">",
"      Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 1983; 309:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/43\">",
"      Bitter MA, Le Beau MM, Larson RA, et al. A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). Am J Clin Pathol 1984; 81:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/44\">",
"      Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986; 68:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/45\">",
"      Liu P, Tarl&eacute; SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/46\">",
"      Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 1995; 85:3695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/47\">",
"      Lutterbach B, Hou Y, Durst KL, Hiebert SW. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A 1999; 96:12822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/48\">",
"      Kogan SC, Lagasse E, Atwater S, et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A 1998; 95:11863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/49\">",
"      Poirel H, Radford-Weiss I, Rack K, et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/50\">",
"      H&eacute;bert J, Cayuela JM, Daniel MT, et al. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 1994; 84:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/51\">",
"      Berger R, Bernheim A, Sigaux F, et al. Acute monocytic leukemia chromosome studies. Leuk Res 1982; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/52\">",
"      Rowley JD. Consistent chromosome abnormalities in human leukemia and lymphoma. Cancer Invest 1983; 1:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/53\">",
"      Kaneko Y, Maseki N, Takasaki N, et al. Clinical and hematologic characteristics in acute leukemia with 11q23 translocations. Blood 1986; 67:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/54\">",
"      Rowley JD. Rearrangements involving chromosome band 11Q23 in acute leukaemia. Semin Cancer Biol 1993; 4:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/55\">",
"      Bernard OA, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer 1995; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/56\">",
"      Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009; 23:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/57\">",
"      Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991; 88:10735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/58\">",
"      Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/59\">",
"      Parkin JL, Arthur DC, Abramson CS, et al. Acute leukemia associated with the t(4;11) chromosome rearrangement: ultrastructural and immunologic characteristics. Blood 1982; 60:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/60\">",
"      Sorensen PH, Chen CS, Smith FO, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994; 93:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/61\">",
"      Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/62\">",
"      Downing JR, Head DR, Raimondi SC, et al. The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 1994; 83:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/63\">",
"      Djabali M, Selleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1992; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/64\">",
"      Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/65\">",
"      Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the \"AT-hook\" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A 1994; 91:10610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/66\">",
"      Caslini C, Shilatifard A, Yang L, Hess JL. The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc Natl Acad Sci U S A 2000; 97:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/67\">",
"      Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/68\">",
"      Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002; 10:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/69\">",
"      Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996; 85:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/70\">",
"      Cozzio A, Passegu&eacute; E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/71\">",
"      Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/72\">",
"      Biswas D, Milne TA, Basrur V, et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A 2011; 108:15751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/73\">",
"      Dobson CL, Warren AJ, Pannell R, et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999; 18:3564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/74\">",
"      Caligiuri MA, Strout MP, Oberkircher AR, et al. The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc Natl Acad Sci U S A 1997; 94:3899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/75\">",
"      Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/76\">",
"      Pintado T, Ferro MT, San Rom&aacute;n C, et al. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1985; 55:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/77\">",
"      Bitter MA, Neilly ME, Le Beau MM, et al. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985; 66:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/78\">",
"      Chang VT, Aviv H, Howard LM, Padberg F. Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature. Am J Hematol 2003; 72:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/79\">",
"      Lugthart S, Gr&ouml;schel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/80\">",
"      Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A 1992; 89:3937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/81\">",
"      Suzukawa K, Parganas E, Gajjar A, et al. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/82\">",
"      Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A 2000; 97:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/83\">",
"      Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/84\">",
"      Langabeer SE, Rogers JR, Harrison G, et al. EVI1 expression in acute myeloid leukaemia. Br J Haematol 2001; 112:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/85\">",
"      Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 1999; 13:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/86\">",
"      Chi Y, Lindgren V, Quigley S, Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008; 132:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/87\">",
"      Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006; 20:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/88\">",
"      Halene S, Gao Y, Hahn K, et al. Serum response factor is an essential transcription factor in megakaryocytic maturation. Blood 2010; 116:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/89\">",
"      Ragu C, Boukour S, Elain G, et al. The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia 2010; 24:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/90\">",
"      Gilles L, Bluteau D, Boukour S, et al. MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood 2009; 114:4221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/91\">",
"      Cheng EC, Luo Q, Bruscia EM, et al. Role for MKL1 in megakaryocytic maturation. Blood 2009; 113:2826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/92\">",
"      Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia 2000; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/93\">",
"      Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/94\">",
"      Duchayne E, Fenneteau O, Pages MP, et al. Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Fran&ccedil;ais d'H&eacute;matologie Cellulaire (GFHC). Leuk Lymphoma 2003; 44:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/95\">",
"      Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/96\">",
"      Wang P, Spielberger RT, Thangavelu M, et al. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer 1997; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/97\">",
"      Rowley JD, Alimena G, Garson OM, et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 1982; 59:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/98\">",
"      Arthur DC, Berger R, Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989; 40:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/99\">",
"      Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood 1992; 80:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/100\">",
"      Rowley JD, Testa JR. Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res 1982; 36:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/101\">",
"      Mitelman F, Nilsson PG, Brandt L, et al. Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1981; 4:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/102\">",
"      Golomb HM, Alimena G, Rowley JD, et al. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 1982; 60:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/103\">",
"      Crane MM, Keating MJ, Trujillo JM, et al. Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. JAMA 1989; 262:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/104\">",
"      Taylor JA, Sandler DP, Bloomfield CD, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/105\">",
"      Meyer M, R&uuml;bsamen D, Slany R, et al. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 2009; 4:e7768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/106\">",
"      Cuiffo B, Ren R. Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood 2010; 115:3598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/107\">",
"      Haferlach C, Dicker F, Kohlmann A, et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/108\">",
"      Ono R, Kumagai H, Nakajima H, et al. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 2009; 23:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/109\">",
"      Sabnis AJ, Cheung LS, Dail M, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009; 7:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/110\">",
"      Crane MM, Strom SS, Halabi S, et al. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev 1996; 5:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/111\">",
"      Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981; 58:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/112\">",
"      Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/113\">",
"      Traweek ST, Slovak ML, Nademanee AP, et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/114\">",
"      Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/115\">",
"      Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     Godley, LA, Larson, RA. Therapy-related myelodysplastic syndrome and myeloid leukemia. In: Myelodysplastic Syndrome: Pathology and Clinical Management, 2nd ed, Steensma, DP (Eds), Informa Healthcare, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/117\">",
"      Arana-Yi C, Block AW, Sait SN, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res 2008; 32:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/118\">",
"      Montesinos P, Gonz&aacute;lez JD, Gonz&aacute;lez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/119\">",
"      Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 2001; 19:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/120\">",
"      Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/121\">",
"      Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/122\">",
"      Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/123\">",
"      Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/124\">",
"      Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C--&gt;T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/125\">",
"      Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/126\">",
"      Smith AG, Worrillow LJ, Allan JM. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007; 109:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/127\">",
"      Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/128\">",
"      Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 1999; 94:3258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/129\">",
"      Arai Y, Hosoda F, Kobayashi H, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood 1997; 89:3936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/130\">",
"      Leonard DG, Travis LB, Addya K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002; 8:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/131\">",
"      Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/132\">",
"      Libura J, Slater DJ, Felix CA, Richardson C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 2005; 105:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/133\">",
"      Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/134\">",
"      Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/135\">",
"      Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997; 94:8732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/136\">",
"      Rowley JD, Reshmi S, Sobulo O, et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997; 90:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/137\">",
"      Shankar DB, Cheng JC, Sakamoto KM. Role of cyclic AMP response element binding protein in human leukemias. Cancer 2005; 104:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/138\">",
"      Hoffmann L, M&ouml;ller P, Pedersen-Bjergaard J, et al. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol 1995; 6:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/139\">",
"      Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/140\">",
"      Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/141\">",
"      Mays AN, Osheroff N, Xiao Y, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010; 115:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/142\">",
"      Andersen MK, Christiansen DH, Jensen BA, et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001; 114:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/143\">",
"      Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004; 104:4210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/144\">",
"      Le Beau MM, Espinosa R 3rd, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A 1993; 90:5484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/145\">",
"      Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997; 94:6948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/146\">",
"      Horrigan SK, Arbieva ZH, Xie HY, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/147\">",
"      Fairman J, Chumakov I, Chinault AC, et al. Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci U S A 1995; 92:7406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/148\">",
"      Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 1994; 19:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/149\">",
"      Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009; 23:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/150\">",
"      Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/151\">",
"      Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/152\">",
"      Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/153\">",
"      Kumar M, Narla A, Nonami A, et al. Coordinate loss of a MicroRNA Mir 145 and a protein-coding gene RPS14 cooperate in the pathogeneiss of 5q- syndrome. Blood (ASH Annual Meeting Abstracts) 2009; 114:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/154\">",
"      Wang J, Fernald AA, Anastasi J, et al. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood 2010; 115:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/155\">",
"      Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/156\">",
"      Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/157\">",
"      Shiseki M, Kitagawa Y, Wang YH, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma 2007; 48:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/158\">",
"      Le Beau MM, Espinosa R 3rd, Davis EM, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/159\">",
"      Fischer K, Fr&ouml;hling S, Scherer SW, et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 1997; 89:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/160\">",
"      McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/161\">",
"      Velloso ER, Michaux L, Ferrant A, et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. Br J Haematol 1996; 92:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/162\">",
"      Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/163\">",
"      Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/164\">",
"      Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/165\">",
"      Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/42/39594/abstract/166\">",
"      Marcucci G, Mr&oacute;zek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005; 12:68.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4544 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39594=[""].join("\n");
var outline_f38_42_39594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H727305333\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE MYELOID LEUKEMIA DE NOVO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H993128343\">",
"      Using cytogenetic analysis to diagnose and classify AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H993127944\">",
"      Using the cytogenetic pattern for AML prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific structural rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - 8;21 translocation in AML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - 15;17 translocation in APL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H993131070\">",
"      - Inv(16) and t(16;16)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H993131111\">",
"      - Rearrangements of 11q23",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - t(3;3) and inv(3) in AML with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H983671238\">",
"      - t(6;9)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H983671253\">",
"      - t(1;22)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H993128835\">",
"      Chromosomal gain and loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ENVIRONMENTAL ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THERAPY-RELATED MYELOID NEOPLASMS (T-MDS/T-AML)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subsets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Following alkylating agents and/or radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Following DNA topoisomerase II inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1052370514\">",
"      - Following bimolane for psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mechanisms of dysplasia and leukemogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - del(5q)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - del(7q)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H826365\">",
"      AML following immunosuppressive and growth factor therapy for aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H826661\">",
"      AML WITH NORMAL KARYOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727305333\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4544|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/1/2073\" title=\"figure 1\">",
"      Chromosomal abnormalities AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4544|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/11/2224\" title=\"picture 1\">",
"      Typical hypergranular APL peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/14/17633\" title=\"picture 2\">",
"      AML FAB M4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/62/19424\" title=\"picture 3\">",
"      AML FAB M4EO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=related_link\">",
"      Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_42_39595="Hypothyroidism in children";
var content_f38_42_39595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hypothyroidism in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chronic autoimmune (Hashimoto's) thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excess iodine ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid damage/infiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        External radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radioactive iodine therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thyroidectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histiocytosis X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Goitrogen ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dietary goitrogens (eg, cassava)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs (eg, thionamides, lithium, anti-convulsants, interferon alfa, tyrosine kinase inhibitors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excess iodine ingestion: Nutritional supplements (eg, iodoral); drugs (eg, amiodarone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Late-onset congenital hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thyroid dysgenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inborn errors of thyroxine synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemangiomas of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothalamic-pituitary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized thyroid hormone resistance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39595=[""].join("\n");
var outline_f38_42_39595=null;
var title_f38_42_39596="IWG response criteria for Hodgkin lymphoma";
var content_f38_42_39596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The International Working Group response criteria for Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Response category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Complete remission",
"       </td>",
"       <td>",
"        No clinical evidence of disease or disease-related symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A post-treatment residual mass of any size is permitted as long as it is PET negative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen and liver must be non-palpable and without nodules.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If a pre-treatment bone marrow biopsy was positive, an adequate bone marrow biopsy (with a core size of at least 20 mm) from the same site must be cleared of infiltrate; if this is indeterminate by morphology, immunohistochemistry should be negative.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Partial remission",
"       </td>",
"       <td>",
"        A decrease by at least 50 percent in the sum of the products of the largest perpendicular diameters (SPD) of up to six of the largest measurable lesions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The post-treatment PET should be positive in at least one previously involved site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There should be no increase in the size of other nodes, liver, or spleen and no new areas of disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenic or hepatic nodules must decrease by at least 50 percent in the SPD (or in the greatest transverse diameter for single nodules).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow biopsy results are not useful in determining PR. However, if the patient otherwise fits the CR criteria but has a positive bone marrow biopsy, the patient is labeled as having a PR.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stable disease",
"       </td>",
"       <td>",
"        Failure to attain a CR or PR with no evidence of progressive disease. The post-treatment PET should be positive at prior sites of disease and no new sites should be present on PET or CT.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Progressive disease or relapse after CR",
"       </td>",
"       <td>",
"        Any new lesion or an increase from nadir by at least 50 percent of previously involved sites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Development of a new lesion is defined by the appearance of any new lesion more than 1.5 cm in long axis. If the long axis diameter is from 1.1 to 1.5 cm, the lesion should only be considered abnormal if its short axis is more than 1.0 cm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive disease is also defined as an increase of at least 50 percent in the longest diameter of a previously identified node more than 1 cm in short axis or in the SPD of more than one node.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lesions should be PET positive unless they are below a detectable size (ie, &lt;1.5 cm in long axis by CT).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The International Working Group response criteria for Hodgkin lymphoma define complete remission, partial remission, stable disease, and progressive disease based upon findings on history, physical examination, computed tomography (CT), positron emission tomography (PET) scan, and bone marrow biopsy (in appropriate cases).",
"    <div class=\"footnotes\">",
"     PET: positron emission tomography; SPD: sum of the product of the diameters; PR: partial remission; CR: complete remission; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39596=[""].join("\n");
var outline_f38_42_39596=null;
var title_f38_42_39597="Mortality metoprolol HF";
var content_f38_42_39597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metoprolol reduces mortality in patients with heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MERIT-HF trial randomly assigned 3991 patients with NYHA class II to IV heart failure who were treated with digoxin, angiotensin converting enzyme inhibitors, and digoxin to metoprolol CR/XL or placebo. Kaplan-Meier curves show a significant reduction in total mortality at 12 months with metoprolol (7.2 versus 11 percent for placebo, p = 0.006).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The MERIT-HF Study Group, Lancet 1999; 353:2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39597=[""].join("\n");
var outline_f38_42_39597=null;
var title_f38_42_39598="Risks and benefits of cough and cold medications for children";
var content_f38_42_39598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the risks and benefits of prescription and over-the-counter medications marketed for the treatment of the common cold in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Active ingredient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential benefits",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential risks*",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Antipyretics/analgesics",
"         </strong>",
"         :",
"        </p>",
"        <p>",
"         Acetaminophen",
"         <br/>",
"         Ibuprofen",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Reduction in temperature; little evidence regarding effects on discomfort",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Acetaminophen may suppress the neutralizing antibody response, resulting in increased nasal secretions and prolonged viral shedding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          First generation antihistamines",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Diphenhydramine",
"         <br/>",
"         Hydroxyzine",
"         <br/>",
"         Chlorpheniramine",
"         <br/>",
"         Brompheniramine",
"         <br/>",
"         Clemastine",
"        </p>",
"       </td>",
"       <td>",
"        Anticholinergic effects decrease mucus secretion",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        No clinically significant benefits",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Sedation",
"         </li>",
"         <li>",
"          Paradoxic excitability",
"         </li>",
"         <li>",
"          Dizziness",
"         </li>",
"         <li>",
"          Respiratory depression",
"         </li>",
"         <li>",
"          Hallucinations",
"         </li>",
"         <li>",
"          Tachycardia",
"         </li>",
"         <li>",
"          Heart block",
"         </li>",
"         <li>",
"          Arrhythmia",
"         </li>",
"         <li>",
"          Dry mouth",
"         </li>",
"         <li>",
"          Blurred vision",
"         </li>",
"         <li>",
"          Urinary retention",
"         </li>",
"         <li>",
"          Dystonic reactions",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Narcotic antitussives",
"         </strong>",
"         <sup>",
"          &Delta;&sect;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Codeine",
"         <br/>",
"         Hydrocodone",
"        </p>",
"       </td>",
"       <td>",
"        Act on cough center in brainstem",
"       </td>",
"       <td>",
"        No more effective than placebo",
"        <sup>",
"         [5,6]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Respiratory depression",
"         </li>",
"         <li>",
"          Nausea",
"         </li>",
"         <li>",
"          Vomiting",
"         </li>",
"         <li>",
"          Constipation",
"         </li>",
"         <li>",
"          Dizziness",
"         </li>",
"         <li>",
"          Palpitations",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Nonnarcotic antitussives",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Dextromethorphan",
"        </p>",
"       </td>",
"       <td>",
"        Act on cough center in brainstem",
"       </td>",
"       <td>",
"        No evidence of effectiveness",
"        <sup>",
"         [5-8]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          CNS effects",
"         </li>",
"         <li>",
"          Serotonin syndrome",
"         </li>",
"         <li>",
"          Hallucinations",
"         </li>",
"         <li>",
"          Respiratory depression (in overdose)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Oral decongestants",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Pseudoephedrine",
"         <br/>",
"         Phenylephrine",
"        </p>",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"       <td>",
"        No evidence of effectiveness in children",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Tachycardia",
"         </li>",
"         <li>",
"          Irritability",
"         </li>",
"         <li>",
"          Agitation",
"         </li>",
"         <li>",
"          Sleeplessness",
"         </li>",
"         <li>",
"          Hypertension",
"         </li>",
"         <li>",
"          Anorexia",
"         </li>",
"         <li>",
"          Headache",
"         </li>",
"         <li>",
"          Nausea",
"         </li>",
"         <li>",
"          Vomiting",
"         </li>",
"         <li>",
"          Palpitations",
"         </li>",
"         <li>",
"          Dysrhythmias",
"         </li>",
"         <li>",
"          Seizures",
"         </li>",
"         <li>",
"          Dystonic reactions",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Topical decongestants",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Oxymetazoline",
"         <br/>",
"         Xylometazoline",
"         <br/>",
"         Phenylephrine",
"        </p>",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"       <td>",
"        No evidence of effectiveness in children",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Rebound nasal congestion",
"         </li>",
"         <li>",
"          Nosebleeds",
"         </li>",
"         <li>",
"          Drying of nasal membranes",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antihistamine-decongestant combination",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Anticholinergic effects (antihistamine)",
"        </p>",
"        <p>",
"         Vasoconstriction (decongestant)",
"        </p>",
"       </td>",
"       <td>",
"        No more effective than placebo",
"        <sup>",
"         [5,9,11]",
"        </sup>",
"       </td>",
"       <td>",
"        See potential risks for antihistamines and decongestants above",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Expectorant",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Guaifenesin",
"        </p>",
"       </td>",
"       <td>",
"        Increase mucus production to make secretions easier to remove with cough or mucociliary transport",
"       </td>",
"       <td>",
"        No studies of effectiveness in children",
"        <sup>",
"         [1,2,5]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild gastrointestinal irritation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Mucolytics",
"         </strong>",
"         <sup>",
"          &Delta;",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         Acetylcysteine",
"         <br/>",
"         Bromhexine",
"         <br/>",
"         Letosteine",
"        </p>",
"       </td>",
"       <td>",
"        Thin secretions to make them easier to clear through coughing",
"       </td>",
"       <td>",
"        Some evidence of improvement compared with placebo",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Bronchospasm",
"         </li>",
"         <li>",
"          Gastrointestinal disturbance",
"         </li>",
"         <li>",
"          Fever",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Topical aromatics",
"         </strong>",
"         :",
"        </p>",
"        <p>",
"         Menthol",
"         <br/>",
"         Camphor",
"         <br/>",
"         Eucalyptus oil",
"        </p>",
"       </td>",
"       <td>",
"        May act on TRPM8 cation channel to produce a cooling sensation",
"       </td>",
"       <td>",
"        <p>",
"         Subjective improvement of nasal patency without objective increase in air flow",
"         <sup>",
"          [12]",
"         </sup>",
"        </p>",
"        <p>",
"         Parental report of symptomatic improvement in nocturnal cough and sleep in poorly blinded study",
"         <sup>",
"          &yen;",
"         </sup>",
"         <sup>",
"          [13]",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        GI and CNS effects may result from accidental ingestion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Ipratropium bromide",
"        </strong>",
"        <sup>",
"         &sect;������",
"        </sup>",
"        (nasal)",
"       </td>",
"       <td>",
"        Decreases nasal discharge via anticholinergic activity",
"       </td>",
"       <td>",
"        May decrease nasal discharge but not nasal congestion",
"        <sup>",
"         [14]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nosebleeds",
"         </li>",
"         <li>",
"          Nasal dryness",
"         </li>",
"         <li>",
"          Headache",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Overdose is a potential risk with all of these agents, particularly when combination products are used.",
"     <br>",
"      &Delta; Because the risks outweigh the proven benefits, these medications generally are not recommended for children younger than six years of age. We suggest not using these medications in children 6 to 12 years of age.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Histamine is not an inflammatory mediator in the common cold.",
"       <br>",
"        &sect; Requires a prescription.",
"        <br>",
"         &yen; Significant placebo effect cannot be excluded.",
"         <br>",
"          ������ For children older than five years.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Pappas DE, Hendley JO. The common cold and decongestant therapy. Pediatr Rev 2011; 32:47.",
"       </li>",
"       <li>",
"        Kelly LF. Pediatric cough and cold preparations. Pediatr Rev 2004; 25:115.",
"       </li>",
"       <li>",
"        World Health Organization. Cough and cold remedies for the treatment of acute respiratory infections in young children, 2001. file://whqlibdoc.who.int/hq/2001/WHO_FCH_CAH_01.02.pdf. Accessed on August 30, 2011.",
"       </li>",
"       <li>",
"        Section on Clinical Pharmacology and Therapeutics, Committee on Drugs, Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 2011; 127:580.",
"       </li>",
"       <li>",
"        Smith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2008; :CD001831.",
"       </li>",
"       <li>",
"        Taylor JA, Novack AH, Almquist JR, Rogers JE. Efficacy of cough suppressants in children. J Pediatr 1993; 122:799.",
"       </li>",
"       <li>",
"        Paul IM, Beiler J, McMonagle A, et al. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med 2007; 161:1140.",
"       </li>",
"       <li>",
"        Paul IM, Yoder KE, Crowell KR, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics 2004; 114:e85.",
"       </li>",
"       <li>",
"        Clemens CJ, Taylor JA, Almquist JR, et al. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children? J Pediatr 1997; 130:463.",
"       </li>",
"       <li>",
"        Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2007; :CD001953.",
"       </li>",
"       <li>",
"        Hutton N, Wilson MH, Mellits ED, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J Pediatr 1991; 118:125.",
"       </li>",
"       <li>",
"        Kenia P, Houghton T, Beardsmore C. Does inhaling menthol affect nasal patency or cough? Pediatr Pulmonol 2008; 43:532.",
"       </li>",
"       <li>",
"        Paul IM, Beiler JS, King TS, et al. Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms. Pediatrics 2010; 126:1092.",
"       </li>",
"       <li>",
"        Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev 2011; :CD008231.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39598=[""].join("\n");
var outline_f38_42_39598=null;
var title_f38_42_39599="Nail changes in psoriasis";
var content_f38_42_39599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Sequential nail changes in psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Mild nail involvement characterized by discrete pits in the nail plate and early onycholytic separation of the lateral edges of the nail plate from the nail bed. These nail changes are the earliest and the most common in psoriasis. Panel B: Moderate nail involvement manifested by the combination of nail plate pitting and more advanced distal onycholysis; the distal third of the nail plate is now separated from the nail bed. Panel C: The most severe and the least common type of psoriatic nail involvement, in which the normal nail plates have been replaced by thickened hyperkeratotic masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Richard D Sontheimer, DM. In: Resource Materials in Rheumatology, number 19: Nail changes in rheumatic diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_42_39599=[""].join("\n");
var outline_f38_42_39599=null;
